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Abstract
Background. Anti-tumor necrosis factor alpha (anti-TNF-a) therapy is used to
treat inflammatory bowel disease. Infrequent but serious adverse events related
to these medications have occurred
Objective. The aim of this meta-analysis is to evaluate the safety of anti-TNF-a
agents in patients with inflammatory bowel disease (IBO).
Methods. Randomized trials that evaluated an anti-TNF-a agent (infliximab,
adalimumab, certolizumab, etanercept, COP 571 and onercept) for the treatment
of IBO were included. The studies had to report on safety and tolerability. Trials
were identified by searching electronic databases and the data were analyzed
using the Cochrane review manager (RevMan 5.1) software.
Results. Twenty four studies were included in the meta-analysis. There was no
statistical difference in the frequency of withdrawal due to adverse events,
serious infections, death, malignancies or tuberculosis between anti-TNF-a and
placebo groups. Placebo patients were more likely to experience a serious
adverse event than patients treated with an anti-TNF-a agent. Patients treated
with anti-TNF-a agents were more likely to develop pneumonia or experience an
infusion reaction than placebo patients. There were no reports of opportunistic
infections, congestive heart failure, or demyelinating disease, for any of the
agents studied. However, post marketing surveillance has shown that patients
are at an increased risk of opportunistic infections. Adverse events with anti-TNF-
a agents were noted to occur irrespective of the indication.
Conclusion. Overall, the results of this meta-analysis demonstrate that the use
of anti-TNF-a agents is safe for patients with IBO.
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Chapter 1. Background
Tumor necrosis factor-alpha (TNF-a) is a cytokine involved in systemic inflammation. It
stimulates an acute phase reaction causing apoptotic cell death, cellular proliferation,
differentiation and inflammation. TNF-a is synthesized initially by activated macro-
phages and T cells as a transmembrane precursor protein and then cleaved to release
soluble TNF-a. It was originally known as cachexin, and was first described in 1975 for
its ability to lyse tumors (Carswell 1975).
It is now known that the biological activity of TNF-a requires the aggregation of three
monomers to form a trimeric structure, which then acts by binding to one of two types of
receptors known as p55 and p75. Activation of these receptors exerts multiple effects
on the immune system, including:
1 stimulation of the release of inflammatory cytokines;
2 upregulation of the expression of endothelial adhesion molecules; and
3 coordination of the migration of leukocytes to targeted organs (Roach 2002).
This immune response has long been implicated in the pathogenesis of ulcerative colitis
(UC) and Crohn's disease (CD). It is also known that the pathogenesis of Inflammatory
Bowel Disease (IBO) is also partly related to the dysregulation of immune responses to
organisms in the intestine (Plevy 1997).
Tumor necrosis factor-alpha (TNF-a) agents represent important treatment advances in
a number of inflammatory conditions. TNF-a agents offer a targeted strategy that
contrasts with the nonspecific immunosuppressive agents traditionally used to treat CD
and UC
Two biologic agents, infliximab and adalimumab have been approved in Canada for the
induction and maintenance of remission in Crohn's disease. Only infliximab is approved
for the induction and maintenance of remission of patient's with UC. A third agent,
certolizumab is approved for the treatment of CD in the United States but is not
available in Canada. COP571, etanercept, and onercept are other TNF-a agents that
have been evaluated for the treatment of IBo but shown to be ineffective.
1.1 Clinical Efficacy
These drugs are often referred to as biologic therapies or biologics because they are
medically engineered antibodies that are designed to work as antagonists to specific
pratein molecules. Clinical trials are carried out as part of drug development to
determine the efficacy, safety and adverse events associated with pharmaceuticals and
other treatments. Trials that analyze biologic therapy are often divided into induction or
maintenance trials depending on the duration of the study. Induction trials are carried
out during an acute flare up of a condition and the main goal is to get the condition
under control and induce remission. Once a chronic condition is in remission the next
step is to ensure that future flares are less likely to occur. Studies that analyze
medications for this purpose are classified as maintenance trials.
1.1.1Infliximab
Infliximab is a chimeric (mouse/human) TNF-a monoclonal antibody comprised of
human (75%) and murine (25%) sequences. It has a high specificity for and affinity to
TNF-a and is available for treatment of moderate to severe Crahn's disease, patients
with fistulizing CO as well as moderate to severe UC. Infliximab neutralizes TNF-a by
inhibiting binding to its receptors and inducing the apoptosis of activated T-Iymphocytes.
(Lugering 1997; Lugering 2001; Van den Brande 2003).
Multiple studies have evaluated the efficacy of infliximab in patients with active Crahn's
disease. The first reported trial was a single dose study carried out in 1995. It included
108 patients with moderate to severe Crohn's disease. At week four, 81 percent of
patients who received infliximab at 5 mg/kg, 50 percent of patients who received 10
mg/kg, and 64 percent of patients who received 20 mg/kg had a clinical response
compared to 17 percent of placebo patients (Targan 1997). Following this initial trial
subsequent studies have shown that scheduled, maintenance therapy with infliximab
has substantial clinical benefits in patients who have achieved remission with induction
therapy. (Feagan 2003; Hanauer 2002; Rutgeerts 1999; Rutgeerts 2004). Two
randomized controlled trials have examined the efficacy of infliximab in patients with
fistulizing Crohn's disease. (Present 1999; Sands 2004). These trials have shown that
significantly more patients receiving infliximab as induction therapy had a reduction in
the number of draining fistulas and demonstrated fistula closure as compared to
placebo. There was also a statistically significant increased likelihood of a sustained
response with infliximab maintenance therapy compared to placebo.
The two largest trials to investigate infliximab for the treatment of UC (ACT 1 and ACT
2) focused on patients with persistently active UC despite treatment with
glucocorticoids, immunosuppressants or aminosalycilates (Rutgeerts 2005). In ACT 1
patients who received infliximab had a clinical remission rate of 34 percent (5mg/kg)
versus 16 percent in the placebo group. The clinical remission rates were similar in ACT
2 at 36 percent for the infliximab group (5mg/kg) compared with 11 percent in the
placebo group
1.1.2 Adalimumab
Adalimumab is a fully human monoclonal TNF-a antibody. Four pivotal studies have
been conducted to evaluate the efficacy of adalimumab as induction and maintenance
therapy of CD. The CLASSIC-I trial included patients with moderate to severely active
CD disease despite conventional therapy. Patients were randomly assigned to placebo
or adalimumab at three different induction doses (40mg/20mg, 80mg/40mg,
160mg/80mg). Remission at four weeks was achieved significantly more often in
patients receiving the induction dose of 160mg followed by 80mg compared with
placebo: 36 versus 12 percent respectively (Hanauer 2006). The CLASSIC-II trial was
a continuation of CLASSIC-I. Fifty-five patients who were in remission at week four of
the CLASSIC-I trial were re-randomized to three treatment groups: placebo,
adalimumab 40 mg every other week or 40 mg weekly for 56 weeks. Of the randomized
patients, remission at week 56 was seen in 79 percent of adalimumab 40 mg every
other week, 83 percent of 40 mg weekly, and 44 percent of those treated with placebo
(Sandborn 2007a).
The "CHARM" trial examined the efficacy of adalimumab for long term maintenance in
854 patients with active disease despite concomitant therapies. All patients received
open label induction therapy with adalimumab (80 mg at week zero and 40 mg at week
two) and were then randomized to maintenance treatment with adalimumab versus
placebo (Colombel 2007). At week 56, remission rates in the 40 mg every other week
(36 percent) and 40 mg weekly groups (41 percent) were significantly higher than with
placebo (12 percent). The GAIN study was a randomized trial that compared
adalimumab to placebo for the induction of remission of CD in patients previously
treated with infliximab. Three hundred and one patients completed the trial. In the
adalimumab group 21% of patients achieved remission compared to 7% of those in the
placebo group (Sandborn 2007b).
1.1.3 Certolizumab
Certolizumab is a humanized monoclonal antibody linked to polyethylene glycol that
neutralizes TNF-a. Polyethylene glycol increases the plasma half-life and may possibly
reduce antigenicity as well. This agent is commercially available in the United States for
the treatment of CD but is not yet available in Canada.
PRECISE 1 was one of the largest studies of certolizumab (Sandborn 2007c). It was a
randomized placebo controlled trial that included 662 patients with moderate-to-severe
Crohn's disease. Patients received certolizumab pegol or placebo at weeks 0, 2, 4 and
then every four weeks. At week 6 and 26 response rates were significantly higher in the
certolizumab group (35 versus 27 and 23 versus 16 percent, respectively). PRECISE 2
was a second randomized trial that included 668 patients with moderate-to-severe CD
who were randomly assigned to certolizumab or placebo (Schreiber 2007). Those who
responded over this initial six week phase were randomly assigned to continue
certolizumab or receive placebo for 26 weeks. Four hundred twenty eight patients (64
percent) had a response during the initial six week period and were continued in the
trial. Maintenance of response was also higher in the active treatment group (63 versus
36 percent) at week 26 compared to placebo (P<0.001)
1.1.4 Other Agents
Three other anti-TNF-a agents have been studied for the treatment of IBo. COP571 is a
humanized monoclonal IgG4 antibody with specificity for TNF-a. It has been prepared
by grafting the complementary determining regions from a rodent antibody onto a
human antibody (Stephen 1995). Five randomized studies have been conducted with
COP571 for the treatment of CO (Feagan 2005; Feagan 2006; Sandborn 2001a;
Sandborn 2004; Stack 1997). These studies have had mixed results. Overall COP571 is
well tolerated and may have some efficacy in the short term but long term it does not
appear to be effective.
Etanercept is a genetically engineered fusion protein. It consists of two identical chains
of the recombinant tumor necrosis factor receptor p75 monomer fused with the Fc
domain of human IgG1. This allows it to bind and inactivate TNF-a (Mohler 1993).
Etanercept is a very effective and safe agent for the treatment of rheumatoid arthritis;
unfortunately it is ineffective for the treatment of CO (Sandborn 2001b).
The final anti-TNF-a agent studied is onercept. It is a soluble human p55 TNF-a
receptor antibody produced by recombinant DNA technology. It neutralizes TNF-a by
forming a high affinity antibody antigen complex. It is well tolerated with a favorable
safety profile but was not effective for treating active CD (Trinchard-Lugan 2001).
1.2 Adverse Events
All of the anti-TNF-a agents studied are generally well tolerated, however a number of
adverse events have been associated with the use of these agents. Most of these
adverse events are minor, however some are quite serious and even fatal. Some of the
most common adverse events are infections (Colombel 2004; Crawford 2008; Curtis
2007; Lichtenstein 2006; Ljung 2004). Patients who are suspected of having any active
infection prior to initiation of an anti-TNF-a agent therapy need to be adequately treated
prior to initiating therapy. Any infection could worsen if an anti-TNF-a agent is used
while the infection is present. Therapy should also be held in patients who develop a
serious infection (Orlando 2008). Serious infections including pneumonia, cellulitis, skin
ulceration, urinary tract infection, and abdominal abscesses have been reported
(Colombel 2004; Lichtenstein 2006; Ljung 2004). More serious and even fatal infections,
including sepsis (ColombeI2004; Ljung 2004), disseminated tuberculosis (Keane 2001),
histoplasmosis (Lee 2002), Pneumocystis carinii pneumonia (Seddik 2004), and
aspergillosis (Tsiodras 2008) have also been reported with the use of these drugs.
Acute infusion reactions have also been described following anti-TNF-a therapy
(Colombel 2004; Ljung 2004). Infusion reactions are characterized by nonspecific
symptoms such as dyspnea, hypotension, and/or urticaria. Infusion reactions are
typically mild and treated by reducing the infusion rate and administration of
acetaminophen and/or antihistamines. Epinephrine or corticosteroids may be required
for severe infusion reactions. Delayed hypersensitivity-like infusion reactions have also
been observed from three days up to two weeks following the first or second reinfusion
These reactions often occur in patients with long intervals between doses and manifest
with myalgia, rash, fever, arthralgia and pruritus. In rare situations patients may even
develop anaphylaxis with hypotension, wheezing, and hives. Localized injection site
reactions have been reported with subcutaneously injected anti-TNF-a agents (Paltiel
2008). Drug induced lupus has also been reported with the use of anti-TNF-a agents
(Colombel 2004; Ljung 2004; Benucci 2008; Maiiosa 2008; Spillane 2007; de Bandt
2005; Elkayam 2004). The exact frequency of the development of these adverse events
has been variable. This is due in part to how the adverse events were categorized,
reported and whether they were attributed to these drugs. The purpose of this meta-
analysis is to evaluate the safety profile of anti-TNF-a agents used in patients with IBD
Chapter 2. Methods
2.1 Objectives
The primary objective of this review was to assess the safety of anti-TNF-a agents used
for the treatment of inflammatory bowel disease.
2.2 Criteria for Considering Studies
Randomized controlled trials comparing anti-TNF-a agents with placebo were
considered for inclusion. The participants in the studies included patients within
specified age ranges with UC or CD diagnosed by a combination of clinical,
radiographic, endoscopic and histologic criteria. In each of the included studies the
participants were randomized to either anti-TNF-a agents or placebo. Standard
medications for the treatment of inflammatory bowel disease were allowed. The studies
had to report on safety and tolerability in order to be included. Trials were identified by
searching electronic databases.
2.3 Outcome Measures
The primary outcome measure of this meta-analysis was the incidence of serious
adverse events while on therapy with either an anti-TNF-a agent or placebo. Other
safety outcomes of interest included: withdrawal due to adverse events, death,
malignancies (including lymphoma), serious infections (e.g. tuberculosis, pneumonia,
abscess formation), infusion reactions and injection site reactions. Extremely rare
events including opportunistic infections, drug induced lupus, congestive heart failure
and demyelinating syndromes were also analyzed. All outcome measures were
expressed as a percentage of the patients' randomized (intention to treat analysis)
2.3.1 Specific Outcomes
An adverse event is defined by the US Food and Drug Administration (FDA) as any
undesirable experience associated with the use of a medical product in a patient For
the purposes of this meta-analysis the following specific rates were analyzed
1. Serious adverse events (SAEs)
• the total number of serious adverse events were recorded for each
of the anti-TNF-a agents and placebo groups.
• the FDA defines a serious adverse event as any undesirable
experience associated with the use of a medical product in a
patient that results in death, hospitalization, disability, a congenital
anomaly or is life threatening.
2. Withdrawals due to adverse events
• the total number of withdrawals due to adverse events were
recorded for each of the anti-TNF-a agents and placebo groups
3. Death
• the total number of deaths were recorded for each of the anti-TNF-
a agents and placebo groups.
4. Malignancy
• the total number of malignancies were recorded for each of the
anti-TNF-a agents and placebo groups.
5. Serious infections
• the total number of serious infections were recorded for each of the
anti-TNF-a agents and placebo groups.
• the types of infections recorded as serious included those infections
associated with death, hospitalization, and the use of intravenous
antibiotics.
6. Tuberculosis (T8)
• TB reactivation, miliary or cavitary TB of the lung or any other body
organ were extracted as a single case of TB
• the total number of cases of TB were recorded for each of the anti-
TNF-a agents and placebo groups.
7. Pneumonia
• the total number of cases of pneumonia were recorded for each of
the anti-TNF-a agents and placebo groups.
8. Abscess
• the total number of cases of an abscess were recorded for each of
the anti-TNF-a agents and placebo groups
9. Infusion reactions
• for intravenous medications, the total number of infusion reactions
were recorded for each of the anti-TNF-a agents and placebo
groups.
10. Injection site reactions
• for subcutaneous medications, the total number of injection site
reactions were recorded for each of the anti-TNF-a agents and
placebo groups.
11. Neurologic side effects, fungal and opportunistic infections were also
recorded when they occurred.
Some patients also withdraw from IBO trials if their symptoms flare during the study
period. From the standpoint of a clinical trial this could result from a lack of treatment in
a placebo group or alternatively a lack of efficacy in a treatment group. In either
situation this is recorded as an adverse outcome and in some cases results in
withdrawal from the study. This does not only occur in IBO trials. Similar observations
have been noted in trials of anti-TNF-a agents for the treatment of rheumatoid arthritis
and psoriasis.
2.4 Post Marketing Surveillance
Before any drug can be marketed in Canada, efficacy and safety must be established.
Rigorous well designed clinical trials are required to generate these data. These trials
often have small numbers of participants and last for a short period of time. The
participants have to meet strict inclusion and exclusion criteria and thus represent highly
selected individuals who differ from those in a community practice. For these reasons
uncommon adverse events may not be detected during a clinical trial.
Post marketing surveillance or pharmacovigilance is defined by the World Health
Organization as "the science and activities relating to detection, assessment,
understanding and prevention of adverse effects or any other drug-related problem
(Harmark 2008)." This information can be ascertained by various means including
spontaneous reporting, intensive monitoring and database studies. It is a vital
component of pharmaceutical evaluation because it is impossible to determine all side
effects of a drug based on clinical trials. A review of post marketing surveillance data
regarding anti-TNF-a agents was conducted as part of this review. The data were
obtained from relevant post marketing publications identified via a literature search. The
data from these studies were then summarized and estimates of adverse events were
determined.
2.5 Search Methods
A computer assisted search of the Cochrane Central Register of Controlled Trials, the
Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group
Specialized Trials Register and the on-line databases MEDLINE and EMBASE was
performed to identify relevant publications between 1966 and November 2010. The
medical subject heading (MeSH) terms "Crohn's disease" or "Colitis, Ulcerative" or
"Inflammatory Bowel Disease", and "anti tumor necrosis factor" or "infliximab" or
"monoclonal antibody cA2" or "Remicade" or "CDP571" or "etanercept" or "onercept" or
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"adalimumab" or "humira" or "d2eT' or "CDP870" or "certolizumab" or "cimzia" were
used to perform key word searches of each database. Manual searches of reference
lists from potentially relevant papers were performed in order to identify additional
studies that may have been missed using the computer-assisted search strategy
Abstracts from meetings were not included because this meta-analysis aimed to
quantify adverse events which are usually considered secondary endpoints and thus not
routinely mentioned in abstracts.
2.6 Data Collection and Analysis
2.6.1 Study Selection
All publications identified by the search strategy were assessed and relevant studies
were selected according to the inclusion criteria. The methodological quality of the
included studies was assessed using the Cochrane risk of bias tool (Higgins 2008)
Factors assessed included
1) sequence generation
• was the allocation sequence adequately generated?
2) allocation sequence concealment
• was allocation adequately concealed prior to randomization?
3) blinding
• was knowledge of the allocated intervention adequately prevented
during the study?
4) incomplete outcome data
• were incomplete outcome data adequately addressed?
5) selective outcome reporting
• are reports of the study free of suggestion of selective outcome
reporting?
6) other potential sources of bias
• was the study apparently free of other problems that could put it at a
high risk of bias?
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A judgment of 'Yes' indicates a low risk of bias, 'No' indicates a higher risk of bias and
unclear indicates an unclear risk of bias. All trials included in this analysis were
randomized, double blind, placebo controlled trials and were deemed to be of a high
quality and at low risk for bias (Appendix A)
2.6.2 Data Extraction
Data were extracted using a prespecified data extraction form (Appendix A). Each trial
was assessed for its methodological quality according the criteria specified above To
ascertain the validity of eligible studies, data were extracted independently by John K
MacDonald, the managing editor of the Cochrane Inflammatory Bowel Disease and
Functional Bowel Disorders Review Group and Gerald S McGrath. Comparison of the
data was carried out and any disagreement was resolved by consensus
The raw data were then analyzed using Review Manager (RevMan 5.1). All data were
analyzed on an intention-to-treat basis. Data were extracted from the original research
articles and converted into 2x2 tables. The presence of significant heterogeneity among
studies was assessed using the chi-square test
For pooled data, summary test statistics were derived using the relative risk and 95%
confidence intervals. A fixed effects model was used for pooling of data. The definitions
of adverse events, including serious adverse events were set by the authors of each
paper, and the data were combined for this analysis only if the definitions were
sufficiently similar
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Chapter 3. Literature Review
3.1 Literature Search
The search for randomized trials identified 352 potentially eligible articles. (Figure 1:
Flow chart for included studies). Twenty four placebo-controlled, randomized trials of
anti-TNF-a agents in adults with ISO fulfilled the inclusion criteria and were included in
the meta-analysis of safety. There were 328 excluded articles which included clinical
reviews, retrospective studies, preliminary results, trials with no placebo group,
subgroup analyses and duplicate publications of RCTs
3.2 Description of Included Studies
Ten studies in this analysis were trials that included infliximab. The first published study,
TARGAN 1997, was a multicenter, double-blind, placebo-controlled induction trial of
infliximab in 108 patients and lasted 12 weeks. Participants had moderate-to-severe CD
and adverse events were recorded at the time of infusion and weeks 2, 4, 8 and 12
The next study, RUTGEERTS 1999 was a randomized, double-blind, placebo-controlled
trial of infliximab in 73 patients. It lasted 36 weeks and safety evaluations were based
on changes in clinical, laboratory, physical examinations and the incidence of adverse
events that patients experienced.
PRESENT 1999 was a randomized multicenter double-blind, placebo-controlled trial of
infliximab in 94 patients with fistulizing CD that lasted 6 weeks. All patients were
evaluated for safety and adverse events during this study.
HANAUER 2002 conducted the ACCENT 1 trial which was a randomized double-blind,
placebo-controlled trial of infliximab as maintenance therapy in 573 patients with active
Crohn's. Over a 46 week period safety analysis and the incidence of adverse events
were recorded.
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Sands 2004 conducted a randomized, double blind, placebo controlled, infliximab
maintenance trial for fistulizing Crohn's disease. The study enrolled 282 patients and
lasted 54 weeks and adverse events were ascertained.
Lemann 2006 conducted a randomized, double-blind, placebo-controlled trial of
infliximab in steroid-dependent CD in 113 patients. During this 52 week trial adverse
events were recorded at each visit and were classified according to severity and
likelihood of relationship to study medication.
Probert 2003 conducted a double-blind, randomized, placebo controlled trial in the
treatment of glucocorticoid resistant UC in 42 patients. The study lasted 6 weeks and
serious adverse events were recorded during the study period and for 30 days after
completion of the trial.
Jarneot 2005 conducted a double-blind, randomized placebo controlled trial in the
treatment of UC in 45 patients refractory to medical therapy over three months. General
side effects were assessed in both placebo and infliximab groups.
Rutgeerts 2005 reported the results of the Active UC Trials 1 and 2 (ACT 1 and ACT 2,
respectively). These were both randomized, double blind, placebo controlled trials that
evaluated the efficacy of infliximab for induction and maintenance therapy for UC. ACT1
lasted 54 weeks and enrolled 364 patients while ACT 2 enrolled 364 patients and lasted
30 weeks. Both studies conducted safety evaluations
Four randomized controlled trials of adalimumab for the treatment of inflammatory
bowel disease were included in the meta-analysis. Colombel 2007 was a randomized,
double-blind, placebo-controlled trial of 778 patients that lasted 60 weeks Efficacy and
safety data were assessed every 2 weeks for the first 8 weeks followed by every 4
weeks until the trial was completed.
Hanauer 2006 was a randomized, double-blind, placebo-controlled trial that evaluated
the efficacy of adalimumab induction therapy in 299 patients with CD over 4 weeks. At
each study visit adverse events were recorded and safety assessments conducted.
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Sandborn 2007A evaluated the long term efficacy and safety of adalimumab
maintenance therapy in Crohn's disease. It was a randomized, double-blind, placebo-
controlled trial that included 276 patients and lasted 56 weeks. Efficacy and safety data
were assessed every 2 weeks for the first 8 weeks followed by every 4 weeks until week
56
Sandborn 20078 was a randomized, double-blind, placebo-controlled trial that
evaluated the effectiveness of adalimumab in 325 patients with CD who had lost
response or were intolerant of infliximab. The trial lasted 4 weeks and adverse events
were recorded through queries, observations by site personnel and patient report.
Certolizumab pegol is a pegylated anti-TNF-a agent and four studies involving this
agent were included in this analysis Winter 2004 was a randomized, double-blind,
placebo-controlled trial that included 92 patients with moderate-to-severe CD who were
followed over a 12-week period. Patients were randomized to certolizumab versus
placebo and monitored for adverse events at each visit.
Schreiber 2005 conducted a 12 week phase II randomized, double-blind, placebo-
controlled trial involving 292 patients. These patients received subcutaneous
certolizumab or placebo and adverse events were monitored for throughout the study
and recorded by the investigator.
Schreiber 2007 reported on a randomized, double-blind, placebo-controlled trial
involving 668 patients that lasted 24 weeks. The efficacy of certolizumab pegol
maintenance therapy versus placebo in adults with moderate-to-severe CD was
assessed. Clinical assessments and adverse event data were recorded every 2 weeks
for the first 8 weeks followed by every 4 weeks until study completion
Sandborn 2007C was a randomized, double-blind, placebo-controlled trial, which
evaluated the efficacy of certolizumab in 660 adults with moderate-to-severe Crohn's
disease. The trial was 26 weeks and safety data were assessed during every clinic visit.
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Sandborn 2001 B reported on etanercept. It was a randomized, double-blind placebo
controlled trial. Forty-three patients with moderate-to-severe CD were enrolled in this 8-
week trial. All adverse events were recorded and graded according to prespecified
criteria.
Stack 1997 tested the hypothesis that CDP571, a genetically engineered antibody to
TNF-a, was effective in the treatment of Crohn's disease. His group conducted a
randomized, double-blind placebo-controlled trial with 31 patients Over the 8 week
duration of the study patients were monitored for adverse events.
Feagan 2005 was a randomized, double-blind placebo controlled trial of CDP571 verses
placebo. Seventy-one patients were followed for 16 weeks for response and the
occurrence of adverse events.
Feagan 2006 was a similar but longer study that was also a randomized, double-blind
placebo-controlled trial of CDP571 verses placebo in 269 patients with corticosteroid-
dependent CD over 32 weeks. Adverse events were assessed at each study visit along
with a physical examination, fistula evaluation, quality of life assessment and laboratory
tests
Sandborn 2001A reported on a randomized, double-blind placebo controlled trial in 159
patients with moderate-to-severe Crohn's disease. The 24-week trial evaluated
response and adverse events to prespecified criteria.
Sandborn 2004 also evaluated CDP571. This randomized, double-blind placebo
controlled trial of 396 patients lasted 24 weeks and adverse events were recorded
Rutgeerts 2006 was a randomized, double-blind, placebo-controlled, dose-ranging trial
that evaluated the efficacy of onercept in 207 patients with Crohn's disease. Safety
outcomes including changes in physical examination, vital signs, laboratory values and
the incidence and severity of adverse events were monitored during the study.
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3.3 Description of Excluded Studies
A total of nine studies were excluded. Sands 2001 was the first study that evaluated the
effect of infliximab on UC. They reported the experience of 11 patients enrolled in a
double-blind, placebo-controlled clinical trial of infliximab for severe, active steroid-
refractory UC. The study was never completed as a result of slow enrollment. Thus
safety data was incomplete and is was excluded.
Baldassano 2003 studied infliximab in a pediatric population. It was excluded because it
was a small open label study and was not placebo controlled. Farrell 2003 initially
conducted a prospective study to evaluate clinical response to infliximab. However all
patients received infliximab and there was no placebo group, thus the study was not
included.
Armuzzi 2004 studied infliximab as a treatment of steroid-dependent UC. This study
was excluded because it was an open label study. Likewise Ochsenkuhn 2004 was a
randomized pilot study of infliximab for acute steroid-refractory UC that was not placebo
controlled and thus it was excluded.
Hyams 2007 also studied infliximab administered to pediatric patients and was not
included because it lacked a placebo arm. Likewise Schroder 2006 was excluded
because it was an open label study and all patients received infliximab. The studies by
Sands 2007 and Van Assche 2008 were not included because patients in both the
active and control arm received infliximab.
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Chapter 4. Data Analysis
Twenty-four trials involving 6395 patients were included. All of these trials included a
safety analysis. There were 4074 patients in the anti-TNF-a groups and 2321 patients in
the control groups.
4.1 Serious Adverse Events
In the overall analysis, there was a small difference in the frequency of serious adverse
events between the anti-TNF-a (n=419) and control groups (n=284): 10.7% versus
12.9%, respectively. The risk ratio for a serious adverse event was 0.83, 95% CI (0.72,
0.95) for anti-TNF-a drugs compared to placebo (Figure 2). In subgroup analysis,
infliximab and adalimumab had slightly fewer serious adverse events than control with a
risk ratio of 0.77, 95% CI (0.64, 0.93) and 0.53, 95% CI (0.37, 0.77) respectively. There
was no statistically significant difference in the frequency of serious adverse events
between anti-TNF-a and control groups for patients treated with certolizumab: risk ratio
of 1.24, 95% CI (0.86, 1.78), COP 571: risk ratio of 104, 95% CI (072, 151),
etanercept: risk ratio of 0.43, 95% CI (0.04, 4.44), and onercept: risk ratio of 1.09, 95%
CI (0.13, 9.04).
4.2 Withdrawal due to Adverse Events
In overall analysis, there was no difference in the frequency of withdrawal due to
adverse events between anti-TNF-a (n=318) and control groups (n=197): 8.2% versus
9.1%, respectively. The risk ratio was 0.87, 95% CI (0.73, 1.04) for withdrawal due to an
adverse event (Figure 3). In subgroup analysis, adalimumab had significantly fewer
withdrawals due to adverse events than control with a risk ratio of 0.50, 95% CI (0.33,
0.75). There was no statistically significant difference in the frequency of withdrawal due
to adverse events between anti-TNF-a and control groups for patients treated with the
other anti-TNF-a agents: infliximab: risk ratio of 1.19, 95% CI (0.82, 1.72), certolizumab:
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risk ratio of 0.85,95% CI (0.62,115), COP 571: risk ratio of 100,95% CI (0.70,145),
etanercept: risk ratio of 4.38, 95% CI (0.22, 86.08), and onercept: risk ratio of 0.51, 95%
CI (0.14, 1.87).
4.3 Deaths
There was a small difference in the frequency of death between anti-TNF-a (n=7) and
control groups (n = 1): 0.21% versus 0.05% respectively, which was not statistically
significant. The risk ratio was 2.03, 95% CI (0.58, 7.07) for the anti-TNF-a drugs versus
placebo (Figure 4). In subgroup analysis, there was no difference in the frequency of
death between anti-TNF-a agents and control arms in clinical trials involving infliximab,
adalimumab, certolizumab, or COP571. There were no deaths reported in randomized
trials involving adalimumab, etanercept or onercept.
4.4 Malignancies
In overall analysis, there was no statistically significant difference in the frequency of
malignancies between anti-TNF-a (n=12) and control groups (n=9): 0.35% versus
046% respectively. The risk ratio was 0.72; 95% CI (0.34, 1.53) for the anti-TNF-a
drugs versus placebo (Figure 5). In subgroup analysis, there was a statistically
significant difference between adalimumab and placebo: two malignancies were
reported in patients receiving placebo and none for those receiving adalimumab.
Otherwise there was no difference in the frequency of malignancies between anti-TNF-a
and control groups involving infliximab, certolizumab, or COP571. There were no
malignancies reported in randomized trials involving etanercept or onercept.
4.5 Serious Infections
In overall analysis, there was no difference in the frequency of serious infections
between anti-TNF-a (n = 97) and control groups (n = 53)· 24% versus 2.3%
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respectively. The risk ratio was 1.00 with a 95% CI (0.71, 1.39) for the anti-TNF-a drugs
versus placebo (Figure 6). No individual anti-TNF-a medications were found to be
statistically different than control groups in subgroup analysis. The risk ratio for
infliximab was 0.86, 95% CI (0.54, 1.37), adalimumab was 0.69, 95% CI (0.34, 1.40),
certolizumab was 2.30,95% CI (0.92, 5.78) and CDP571 was 1.35, 95% CI (0.46,4.00).
4.6 Tuberculosis
In overall analysis, there was a slight difference in the frequency of tuberculosis
between anti-TNF-a (n = 3) and control groups (n = 0): 0.13% versus 0 respectively.
The risk ratio was 1.89, 95% CI (0.31, 11.69) for the anti-TNF-a drugs versus placebo
and this was not statistically significant (Figure 7). In subgroup analysis, there was no
difference in the frequency of tuberculosis between anti-TNF-a and control groups for
infliximab or certolizumab.
4.7 Pneumonia
The frequency of pneumonia was higher in the anti-TNF-a (n = 13) group versus control
groups (n = 1): 08% versus 0.1%. However, the risk ratio was 2.54, 95% CI (0.75, 859)
for the anti-TNF-a drugs versus placebo (Figure 8). This was not a statistically
significant difference but clearly there was a tendency towards patients treated with anti-
TNF-a to develop pneumonia more frequently than patients treated with placebo. In
subgroup analysis, there was no difference in the frequency of pneumonia between
anti-TNF-a and control groups for infliximab, adalimumab or certolizumab.
4.8 Abscess
There was no difference in the frequency of abscess formation between anti-TNF-a
(n=55) and control groups (n=45): 2.1 % versus 2.6% respectively. The risk ratio was
0.93, 95% CI (0.63, 1.37) for the anti-TNF-a drugs versus placebo (Figure 9) In
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subgroup analysis, there was no difference in the frequency of abscess between anti-
TNF-a and control arms in clinical trials involving infliximab, adalimumab, certolizumab,
or COP571.
4.9 Infusion Reaction
Infliximab and COP571 are agents that are infused There was a difference in the
frequency of infusion reactions between anti-TNF-a (n=276) and control groups
(n=103), 15.3% versus 10.0% respectively. The risk ratio was 1.50, 95% CI (121,186)
for the anti-TNF-a drugs versus placebo. (Figure 10) In subgroup analysis, infliximab
had a risk ratio of 1.47; 95% CI (1.11,1.93). There was also a difference for COP 571
with a risk ratio of 1.57; 95% CI (1.12, 2.50) compared to placebo.
4.10 Injection Site Reaction
In overall analysis, there was no difference in the frequency of injection site reactions
between anti-TNF-a (n=199) and control groups (n=113), 9.39% versus 9.49%
respectively. The risk ratio was 0.91, 95% CI (0.71, 1.18) for the anti-TNF-a drugs
versus placebo. (Figure 11) In subgroup analysis, there was no difference in the
frequency of injection site reactions for etanercept or onercept. There were actually
more injection reactions noted for patients who received placebo compared with
certolizumab with 4.7% versus 13.0% respectively. The risk ratio was 0.37, 95% CI
(0.25, 0.56). In the case of adalimumab 11.9% patients experienced an injection
reaction compared to 6.2% of those receiving control. The risk ratio was 1.79, 95% CI
(1.22, 263).
4.11 Other Events
There were no reports of opportunistic infections, congestive heart failure or
demyelinating disease for any of the agents studied. There was one reported case of
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drug induced lupus. This occurred in a patient receiving infliximab. Studies involving
Certolizumab and CDP571 also measured this outcome but reported no cases.
4.12 Heterogenity
The presence of heterogeneity among studies was assessed using the chi-square test
of homogeneity and a fixed-effect model. Statistically significant heterogeneity was
found for withdrawal due to adverse events and injection site reactions (P=0.003 and
P<0.00001, respectively).
On review of these individual analyses it was found that statistical heterogeneity was
present because of one particular trial. Hanauer 2002 had 45 withdrawals from the 385
patients in the infliximab group and only 5 withdrawals from 188 patients in the placebo
group. These proportions were different from the other trials with infliximab. Further
analysis revealed this trial accounted for all of the heterogeneity.
The other outcome with heterogeneity was injection site reaction. Two of the
certolizumab studies accounted for this result. The studies Sandborn 2007C and
Schreiber 2007 had less injections reactions in patients who received certolizumab
compared to control. There were also proportionately less injection reactions for
certolizumab in these studies compared to the third certolizumab study, Schreiber 2005
and all of the adalimumab studies.
4.13 Bias
Funnel plots in which the treatment effects from individual studies on the horizontal axis
are plotted against a measure of study precision on the vertical axis are used to detect
publication bias in meta-analysis. In the absence of bias the graph resembles a
symmetrical inverted funnel. This occurs because the treatment effect estimates from
smaller studies scatter more widely at the bottom of the graph and the spread narrows
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with increasing precision among larger studies. If there is publication bias because
smaller studies which show no statistically significant effects remain unpublished then
the funnel plot will appear asymmetrical
For this analysis a funnel plot of trials performed for the primary outcome, serious
adverse reaction was symmetrical, suggesting the absence of publication bias (Figure
12).
4.14 PRISMA
This meta-analysis was conducted and reported in accordance with "The PRISMA
Statement: Preferred Reporting Items for Systematic Reviews and Meta-Analyses."
(Mohler 2009) Appendix C includes a checklist that outlines the topics that encompass
the PRISMA requirements and outlines the corresponding sections in this document
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Chapter 5. Post Marketing Surveillance
The first post marketing surveillance data published regarding the use of anti-TNF-a
agents in patients with inflammatory bowel disease was a retrospective cohort study
from the Mayo clinic (Colombel 2004). It evaluated the short and long-term safety of
infliximab. This group reviewed the medical records of 500 consecutive patients who
received a median of 3 infusions of infliximab and had a median follow-up of 17 months.
They calculated an intrinsic likelihood (imputability) score to determine the likelihood of
a causal relationship to infliximab for each adverse event. Overall forty-three patients
(8.6%) experienced a serious adverse event and thirty of these events were felt to be
related to infliximab. The most commonly reported events were infections which
occurred in 48 patients and 41 (8.2%) of these were attributed to infliximab. Twenty
patients had a serious infection: fatal sepsis (2), pneumonia (8), viral infections (6),
abdominal abscesses (2), cellulitis (1), and histoplasmosis (1). Three of nine reported
malignancies were possibly related to infliximab. Five deaths occurred which were
possibly related to infliximab. Acute infusion reactions occurred in 19 of 500 patients
(3.8%) and serum sickness-like disease was attributed to infliximab in 14 patients
(2.8%). Three patients developed drug-induced lupus and one patient developed a new
demyelinating disorder.
Shortly after the Mayo review a European study was also published that analyzed
serious adverse events associated with infliximab (Seiderer 2004). This group
retrospectively analyzed the charts of 100 patients for acute and sub-acute adverse
events. Their results were based on data from 322 infusions. Generally infliximab
therapy was well tolerated and no deaths, malignancies, autoimmune diseases,
tuberculosis, neurologic or cardiac adverse events were reported. Only 10 patients
experienced adverse events: 2 patients suffered an acute infusion reaction, 1 developed
serum sickness, 4 patients had a bacterial or viral infection and one 1 developed
pancytopenia.
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A similar analysis was also conducted in Sweden (Ljung 2004). A cohort of 217 IBo
patients treated with a mean of 2.6 infliximab infusions between 1999 and 2001 were
assessed for adverse events. Forty-two severe adverse events were registered in 41
patients. Three patients developed lymphoma which was fatal in two, opportunistic
infections occurred in two patients (one was fatal), and two patients with severe attacks
of ISO died due to sepsis (one with CD, one postoperatively with UC). One additional
patient with UC died from a pulmonary embolism after colectomy. The authors
concluded that Infliximab was efficacious however they noted that adverse events were
an issue in elderly patients with severe attacks of IBo.
The TREAT (Crohn's Therapy Resource, Evaluation and Assessment Tool) registry has
enrolled thousands of patients who have been treated with infliximab and other
therapies (Lichtenstein 2006). One of the goals of this database is to assess the long-
term safety of these medications. Lichtenstein 2006 has published data regarding
6,290 patients enrolled in the registry. Infliximab was given to 3,179 patients
representing 5,519 patient-years of follow up and 3,111 patients received other
therapies representing 6,123 patient-years of follow up. The mortality rates were similar
for infliximab- and non-infliximab-treated patients (0.53 per 100 patient-years compared
to 0.43 patient-years; relative risk, 1.24; 95% CI, 0.73-2.10). Multivariate logistic
regression analysis determined that serious infections were most likely due to the
development of moderate to severe CD (HR 2.46, P<0.001) and the use of prednisone
or narcotics more than doubled the risk of a serious infection (P<0.001). Prednisone
was also associated with an increased risk of mortality (odds ratio [OR], 2.10; 95% CI
(1.15-3.83); P=0.016). The group also found that about 3.3% of infliximab infusions
resulted in an infusion reaction. However, only 0.08% of reactions were serious. There
was no difference in deaths between the two groups.
A Spanish group carried out a multicenter retrospective survey of all 169 CD patients
treated with infliximab at 8 University hospitals (Gonzalez-Lama 2008) The patients
were followed for an average of 28 months and safety data was one of the parameters
analyzed. This analysis included data from 1,355 infliximab infusions. Infusion reactions
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occurred in 17 patients (1.2% of the infusions). Only one case was a severe infusion
reaction the remaining 16 were mild. Other minor adverse events occurred in 26% of
the patients and were the cause of treatment withdrawal in 7 patients (4.1 %)
Fiddler 2009 conducted a study involving 734 patients with IBO who were followed for a
median of 58 months. This cohort consisted of patients who were treated over a 14-year
period. The group also evaluated 666 control patients not treated with infliximab for
adverse events. One hundred twelve serious adverse events occurred in 93 patients
(13%) treated with infliximab compared to 157 serious adverse events in 126 (19%)
control patients with an odds ratio of 1.33, 95% CI (0.56, 3.00), p=0.45. There was no
difference between the two groups in mortality, malignancies and infection rate. TB was
the most serious infection that occurred in two patients receiving infliximab. Interestingly
two of these patients had a negative skin test whereas none of the 16 patients with a
positive skin test who received prophylaxis developed TB. The only significant
independent risk factor for infections in patients treated with infliximab was concomitant
treatment with steroids with an odds ratio of 2.69,95% CI (1.18, 6.12), P=0018
The Leuven group conducted a similar large observational study that assessed the
long-term use of infliximab in 614 consecutive patients with CO (Schnitzler 2009). These
patients had a median follow-up of 55 months. Withdrawal due to adverse events
occurred in about 12.8% of patients and 6% developed delayed infusion reactions.
Three patients died while on treatment: one developed Aspergillus infection, one
sudden death occurred and one patient developed pancreatic cancer. They also found
there was a greater need for hospitalizations and surgery in the patients that received
episodic treatment with infliximab. Patients in the regularly scheduled group were also
more likely than those in the episodic group to discontinue steroids.
A Hungarian study recently reported the nationwide, multicenter experience with
infliximab therapy for CD (Mineller 2009). Over a 6-year-period this group treated 363
patients with infliximab. Adverse events included 34 allergic reactions (9.4%), 17
delayed type hypersensitivity (4.7%),16 infections (4.4%), and 3 malignancies (0.8%).
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Another small study examined the induction and maintenance responses to infliximab in
an outpatient inflammatory bowel disease clinic (Teshima 2009). This Canadian group
conducted a retrospective chart review and they also analyzed for adverse events.
Fifteen of 117 patients (12.8%) reported nine infusion reactions, four serum sickness-
like reactions, one rash and one infection. No serious infections, malignancies or
neurological adverse events were encountered.
Two hundred ninety-seven consecutive patients with CD treated with infliximab at the
Beth Israel Deaconess Medical Center were reviewed for adverse events (Hamzaoglu
2010). This group of patients received a total of 1794 infusions with a median of 4
infusions per patient. Forty-four patients (15%) experienced a serious adverse event.
Eighteen patients (6%) had an acute infusion reaction resulting in respiratory problems
in 10 patients (3%), an anaphylactoid reaction in one patient (0.3%) and serum sickness
in one patient (03%). Three patients (1%) developed drug-induced lupus and one
patient developed a possible new demyelinating disorder. Eight patients (2.7%)
developed a serious infection, all of whom were on concurrent immunosuppressants
and one of these infections resulted in fatal sepsis. Six patients (2%) developed
malignancies including two lymphomas and two skin cancers
Zabana 2010 evaluated the long-term safety profile of infliximab over a nine year period
with a median of five infusions per patient. All IBD patients treated with infliximab were
registered and adverse outcomes recorded. One hundred fifty-two patients with a
median of five infliximab infusions were included. Thirteen percent had an infusion
reaction, twenty patients had a viral or bacterial infection and two patients developed
neoplasia. This was over a median of one hundred forty two infusions. Overall the rate
of serious adverse events was less than 10%.
A review regarding the safety of infliximab in a cohort of 120 pediatric patients under the
age of 17 was published in 2011 (Cromb 2011). The median duration of follow up was
32 months. This cohort of patients included 50 (42%) who received episodic treatment
and 70 (58%) who received maintenance therapy. Infliximab efficacy was defined as
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those still responding to infliximab at their last visit and those who stopped infliximab
while in remission. The infliximab failure group included patients who stopped due to
adverse events and nonresponders. The risk of surgery was reduced (p=0.009) in the
infliximab group and lower in patients with scheduled therapy compared to episodic
therapy (p=0.03). Patients in the infliximab group also had significant catch-up growth
(p=0.04), while those who failed infliximab did not. The conclusion was that long-term
infliximab use resulted in a lower rate of surgery and improved catch-up in growth,
especially when receiving scheduled therapy. Hyams et al. also assessed the long-term
effects of maintenance infliximab therapy in 60 children (Hyams 2011). Six children had
serious infections, the most common being upper respiratory infections.
Lees 2009 reviewed 202 patients who received anti-TNF-a agents (adalimumab and
infliximab) in Edinburgh from 1999 to 2007. The most common adverse events reported
were infections. A total of 42 patients experienced at least one infection. A total of 6
malignancies, 3 hematological and 3 bronchogenic lung cancers were reported. Four of
these occurred 20 months or longer after the last infliximab infusion. The other two were
diagnosed within 4 to 8 weeks of the last infusion.
Adalimumab was approved for use in Canada during 2007 thus there is not as much
clinical experience with it. Recently, publications have reported post marketing data on
this agent. Nichita et al. assessed the long-term effectiveness and safety of adalimumab
in a multicenter cohort of 55 patients over a three year period (Nichita 2010). Only a few
minor adverse events were reported and adalimumab was well tolerated in patients with
moderate-to-severe CD, demonstrating sustained long-term efficacy
The Scottish Society of Gastroenterology also evaluated the efficacy and safety of
adalimumab (Ho 2009). They identified and followed up on the clinical outcomes of
patients with CD treated with adalimumab over a 4-year period (2004 to 2008). Ninety
eight patients received adalimumab and there was over 100 patient years of follow-up
recorded. Overall eight had nonfatal serious adverse events. However there were two
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case fatalities: one patient developed sepsis following perforation and another had
disseminated colorectal cancer.
Swoger 2010 reviewed 118 patients who were prescribed adalimumab for CD between
January 2003 and June 2007. Sixty-four patients (54%) experienced a total of 117
adverse events and thirteen of these patients (11 %) experienced 15 serious adverse
events. A total of 16 patients (14%) discontinued adalimumab due to an adverse event.
5.1 Temporal Trends Based on Post Marketing Surveillance
The temporal developments of adverse events were analyzed as part of this review.
The initial data from the Treat registry were combined with the post marketing data and
a pooled estimate was calculated for four specific outcomes: death, malignancy, serious
infections and tuberculosis (Table 1). Likewise the five year Treat data were used in
combination with the post marketing data to determine a pooled estimate for these
outcomes.
The combined post marketing surveillance data are presented in Table 1. Based on this
information the overall risk of death was 6.6 per 1000 patients. When the initial Treat
data and five year Treat data were included this number increased to 7.7 and 17.2
respectively. A similar temporal increase was seen with respect to the risk of
malignancy and serious infections. The corresponding combined post marketing data
showed an increase from 13.5 to 18.0 cases of malignancy per 1000 patients and the
overall risk of serious infection went from 33.5 to 72.1. It is interesting to note that the
risk of developing tuberculosis was constant over time.
The development of adverse events associated with Anti-TNF-a agents appears to
increase over time. Table 1 also shows the rates of each of these events based on the
meta-analyses. The risk of death was 2.0 (events per 1000 patients), malignancy 4.0
and serious infection 24. It is no surprise that the results from the meta-analysis are
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much lower than those from the post marketing data. The results obtained from the post
marketing studies cover a longer duration of time; up to 5 years in the case of the Treat
data. The information in the meta-analysis is based on randomized trials that ranged in
durations from 4 to 56 weeks. The post marketing data also contains information on a
broad range of patients with Crohn's disease. This group of patients were not subject to
the strict inclusion and exclusion criteria that was applied to the group of patients
included in the data from randomized trials.
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Chapter 6. Discussion
Patients with IBO have a tendency toward a variety of co-morbidities. Compared with
healthy individuals in the general population, they are known to have an increased risk
of infection, TB, solid tumors, lymphoma, and demyelinating disorders (Marehbian
2009). The rates of these conditions have been shown to be higher in patients with
poorly controlled disease. Regimens used to treat moderate-to-severe IBO have also
been associated with an increased risk of some of these adverse events. As a result
physicians have often limited the use of certain drugs to treat IBO. Anti-TNF-a agents
are a relatively new pharmacological class of drugs that are very effective for treating
IBO but fall into this category.
The safety profile of anti-TNF-a agents is a timely issue because the use and
indications for these drugs are rapidly increasing. Safety data available from 24
controlled trials of up to 60 weeks in duration for CO and UC were included in this meta-
analysis. This study specifically evaluated the safety outcomes of anti-TNF-a therapy in
IBO to determine the risk of adverse outcomes associated with these drugs.
Our analysis included 6395 patients and it revealed that there was no statistically
significant difference between anti-TNF-a therapy and placebo with respect to increased
risk of serious adverse event, withdrawal due to an adverse event, death, or
malignancy. Subgroup analysis for infliximab, certolizumab, COP571, etanercept and
onercept revealed no difference between these agents and control. However placebo
treated patients in the adalimumab studies did have a slightly increased risk of having a
serious adverse event and withdrawal due to an adverse event (Colombel 2007). This
occurred because exacerbation of Crohn's disease, was the most common serious
adverse event affecting 32.2% of placebo patients and only 19.1 % of patients treated
with adalimumab. This was also the most common reason for withdrawal from the study
for patients in the placebo group.
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Regarding overall safety, the results of this meta-analysis did not show a statistically
significant difference between anti-TNF-a therapy and placebo with respect to mortality,
serious infection, or malignancy. However these results need to be interpreted with
caution. The risk ratio was 2.03 for mortality from anti-TNF-a drugs compared to
placebo and the mortality rate was 0.21% for anti-TNF-a drugs versus 0.05% in the
control group. Thus there was a tendency to increased mortality even though the result
was not statistically significant.
Perhaps the most pertinent clinical concern with the use of biological agents is the risk
of serious infections. Our analysis revealed no statistically significant difference
between anti-TNF-a and placebo for serious infection, tuberculosis, pneumonia or
abscess. Subgroup analysis for each of these parameters also revealed no statistically
significant difference with any of the pharmacological agents included in this analysis.
However the risk ratio was 2.3 for a serious infection with the use of certolizumab. This
indicates that there was a tendency for patients to develop serious infections with this
medication. Although the result was not statistically significant this is noteworthy from a
clinical standpoint.
Other authors have found similar results when analyzing the risk of developing a serious
infection in patients with IBO who have been treated with anti-TNF-a agents (Colombel
2004; Curtis 2007; Lichtenstein 2006; Ljung 2004). It has been noted that the baseline
risk of serious infection is much higher in IBO than other autoimmune conditions. Since
IBO is a chronic disorder that involves a breakdown of the mucosal barrier of the gut,
patients are at increased risk of abscess formation, sepsis and perianal disease
(Lichtenstein 2006; Orlando 2008). Patients with other inflammatory and autoimmune
conditions are not as vulnerable to infection as patients with IBO.
There were three cases of tuberculosis reported in patients treated with anti-TNF-a
agents and none in the placebo group. The risk ratio was 1.89 and this was not
statistically significant. However from a clinical standpoint it is concerning that three
patients developed tuberculosis since these patients were each screened with a chest
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x-ray and TB skin test prior to initiating therapy with an anti-TNF-a agent. This raises the
question as to whether TB skin testing is adequate screening prior to commencing
therapy with an anti-TNF-a agent.
Both upper and lower respiratory tract infections have been recognized as a
complication of therapy with anti-TNF-a agents (Colombel 2004; Crawford 2008; Curtis
2007; Ljung 2004; Lichtenstein 2006; Orlando 2008). This study specifically analyzed
pneumonia and the risk ratio for the development of pneumonia was 2.54 for patients
treated with an anti-TNF-a agent compared to placebo. Although this was not a
statistically significant result the frequency of pneumonia was 0.8% for the anti-TNF-a
group compared to 0.1 % for placebo. Since this is a clinically relevant result, physicians
and patients on these agents need to be vigilant with respect to symptoms suggesting a
respiratory tract infection.
Two anti-TNF-a agents are infused: infliximab and CDP571 and there were slightly
more infusion reactions with these agents compared to placebo. This is an expected
result. Nurses and physicians closely monitor patients in clinical settings where these
agents are given and protocols are in place to deal with reactions. The remainder of the
anti-TNF-a agents are given via injection and overall there was no difference for
injection site reactions compared with placebo. Subgroup analysis did reveal
adalimumab caused more injection site reactions than placebo; these were localized
reactions and are monitored for in clinical practice and treated accordingly
6.1 Biologic Use and Modern Medicine
Biologic agents or "biologics" refer to a class of therapeutic agents that are produced by
means of biological processes involving recombinant DNA technology. These
medications have had a profound impact on many medical fields, primarily
rheumatology, oncology, dermatology and gastroenterology. In each of these
disciplines, biologics have added major therapeutic options for the treatment of many
diseases. Some of these conditions had no effective therapies or previously existing
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therapies were clearly inadequate. Biologic medications usually fall into one of three
categories:
1. Substances identical or nearly identical to the body's own signaling proteins.
Examples are the blood-production stimulating protein erythropoietin, growth
hormone, or biosynthetic human insulin.
2. Monoclonal antibodies. These are custom-designed antibodies similar to those
that the immune system uses to fight off bacteria and viruses. They are made
specifically to counteract or block a given substance in the body, or to target a
specific cell type.
3 Receptor constructs. These are fusion proteins based on a naturally-occurring
receptor linked to an immunoglobulin frame. These agents block the receptor
thereby reducing the inflammatory cascade.
Patients who receive certain biologic therapies are at an increased risk for adverse
events including infection and malignancy. However, when standard therapies are
ineffective, biologic therapies may offer an effective alternative despite the increased
risk
6.1.1 Combination Therapy
Another long standing issue is whether combination therapy with immunosuppressive
agents or steroids may also have an impact on the long term safety profile of these
medications. The concern of combination therapy with infliximab and azathioprine was
addressed by the SONIC trial (ColombeI 2010). This study had three treatment arms:
azathioprine (an immunosuppressant) alone, infliximab alone and azathioprine in
combination with infliximab. It was not included in our analysis because it was not
placebo controlled. One of the endpoints addressed in this study was the occurrence of
adverse events.
The results of this trial revealed that the percentage of patients with any adverse event
was the same across all three treatment arms. However 26.7% of patients in the
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azathioprine group developed a serious adverse event compared to 23.9% for the
infliximab group and 15.1 % for the combination group. Withdrawal from the study was
highest in the azathioprine arm at 26.1 %, while it was 20.7% for combination therapy
and 17.8% for the infliximab group.
The risk of serious infection has also been a major concern with the use of combination
therapy. The SONIC trial found that the rate of serious infection was 3.9% for the
combination group, 4.9% for the infliximab group and 5.6% for the azathioprine group.
The corresponding results for any infection were 41.9%, 46.0% and 45.3% respectively
Based on the results of this well organized randomized control trial is appears that the
combination of azathioprine and infliximab is safe.
6.1.2 Treat Registry
Another valuable source of information on biologics is the Treat (Crohn's Therapy
Resource, Evaluation and Assessment Tool) registry (Lichtenstein 2006). The
participants in this cohort study are still being followed and data regarding their health
status is being recorded. Five years ago based on TREAT data Lichenstein published a
report assessing the safety of immunosuppressants and infliximab used for the
treatment of Crohn's disease. At that point in time, data were available for 3,179
patients who had received infliximab. The analysis involved 5,519 patient-years of follow
up or 1.7 years per patient receiving infliximab. They found that mortality rates were
similar for infliximab and non-infliximab treated patients, that serious infections were
most likely due to the development of moderate to severe Crohn's disease, the use of
prednisone or the use of narcotics. Prednisone was also associated with an increased
mortality risk.
The group analyzing the TREAT registry has recently reported data based on
approximately five years of follow-up on 6273 patients at Digestive Disease Week 2011.
Lichenstein 2011 reported data on 6273 patients with an average follow-up of 5.2 years.
His group found that the mortality rates were similar for infliximab and non-infliximab
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treated patients at 0.56 and 0.62 deaths per 100 patient years respectively. With
respect to serious infections the risk factors were the same as the initial findings of the
Treat registry with one difference. The updated results revealed that infliximab was
associated with an increased risk of serious infections. Prednisone use and narcotics
were associated with an increased risk of mortality and serious infection.
6.1.3 Reviews of Biologic Agents used for IBO
There have been three smaller meta-analyses of biologic therapies for the treatment of
inflammatory bowel disease that have reported results regarding adverse events.
Peyrin-Biroulet 2008 conducted the first reported meta-analysis of placebo-controlled
trials to evaluate the safety and efficacy of anti-TNF-a agents for Crohn's disease. The
review analyzed 21 studies enrolling 5356 individuals, with 3341 patients in the anti-
TNF-a groups and 2015 patients in the control groups. In their overall analysis Peyrin-
Biroulet found no statistically significant difference in the frequency of death between
anti-TNF-a and control groups (0.21 % versus 0.05%). In subgroup analysis, Peyrin-
Biroulet also found no statistically significant difference in the frequency of death
between anti-TNF-a and control arms for induction trials or maintenance trials. Our
results found a similar frequency of death between anti-TNF-a and control groups
(0.21 % versus 0.04%, respectively; and a RR 2.03, 95% CI (0.58, 7.07).
With respect to malignancies Peyrin-Biroulet found no difference in the frequency
between anti-TNF-a and control groups (0.24% vs. 0.39%). Our results were similar with
the frequency of malignancy between anti-TNF-a and control groups (0.35% versus
0.46%, respectively; and a RR 0.72, 95% CI, 0.34-1.53). Peyrin-Biroulet also found no
difference in the frequency of serious infections between anti-TNF-a and control groups
(2.09% vs. 2.13%). The results reported in our analysis were similar with no difference
between the frequency of serious infections between anti-TNF-a and control groups
(2.37% versus 2.31%, respectively; RR 1.00, 95% CI (0.71-1.39).
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Another small meta-analysis of randomized control trials provided a comprehensive
review of the efficacy and safety of certolizumab in Crohn's disease. (Shao 2009) For
this safety analysis 1313 patients who had received continuous treatment with
certolizumab 400 mg were included. They concluded there was no apparent relationship
between certolizumab exposure and the following adverse events: malignancies,
lymphoma, tuberculosis and death. The only exception was with the development of
infections. The risk of infection increased with longer duration of exposure in both
certolizumab-treated (47.5% (;::4 weeks duration) vs. 60.6% (;::6 months duration)) and
placebo-treated (31.7% (;::4 weeks) vs. 40.7% (;::6 months)) patients. The subgroup
analysis for our meta-analysis found a trend for patients treated with certolizumab to
development clinically relevant infections and the temporal analysis revealed that the
risk of infection increased with the duration of treatment.
A third meta-analysis (Siegel 2009) was reported that specifically addressed the risk of
lymphoma associated with the combination of an anti-TNF-a and an immunomodulator.
There is a concern that the combination of these drugs might increase the risk of
lymphoma. In particular, some case reports of a particularly rare and aggressive form of
hepatosplenic T-cell lymphoma have been associated with combination therapy. (Thai
2010) Siegel's meta-analysis was performed to determine the rate of non Hodgkin's
lymphoma (NHL) in adult CD patients receiving dual therapy. The final report included
twenty-six studies involving 8905 patients and 21,178 patient-years of follow-up. The
analysis contained a variety of studies including nine randomized trials, three cohort
studies and 14 case series.
Patients on combined therapy were compared to a population-based registry and to a
population of CD patients treated with immunomodulators. Among anti-TNF-a treated
subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years) and the majority
of these patients had previous immunomodulator exposure. Compared with the
expected rate of NHL (1.9 per 10,000 patient-years), anti-TNF-a treated subjects had an
elevated risk (standardized incidence ratio, 3.23; 95% confidence interval, 1.5-6.9).
When CD patients treated with anti-TNF-a were compared with CD patients treated
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with only immunomodulators (4 cases of NHL per 10,000 patient-years), the
standardized incidence ratio was 1.7 (95% confidence interval, 0.5-7.1). This indicates a
slightly increased risk of lymphoma attributable to these agents.
The results from our meta-analysis included trials that reported two cases of lymphoma
(Sandborn 2007a, Rutgeerts 1999) Both of these cases were included in the meta-
analysis by Siegel. His meta-analysis included more episodes of lymphoma because it
also included cohort studies and case series. In particular he included data from the
Treat registry as well as the study by LJUNG 2004. These two cohorts included a total
of nine patients who developed lymphoma. In the post marketing analysis we conducted
we also found that the cases of lymphoma reported after anti-TNF-a agents entered the
marketplace increased. Essentially both this review and Siegel's meta-analysis have
similar results: the number of case of lymphoma during randomized control trials is low
and it slightly increases with the extended use of these drugs once they are in
widespread use.
6.1.4 Cochrane Collaboration on Biological Agents
Recently the Cochrane collaboration published a systematic review regarding the
adverse effects of biologics. This group explored the adverse effects of numerous
biological agents including anti-TNF-a agents, interleukin (IL)-1 agent, IL-6 agent, anti-
CD28 (abatacept), and anti-B cell therapy in patients with any disease condition except
HIV (Singh 2011).
The analysis included 163 randomized controlled trials with 50,010 participants. They
also analyzed a further 46 open-label extension studies which enrolled 11,954
participants. When all biologic agents were grouped and compared to control, the rates
of serious adverse events, serious infections, lymphoma, and congestive heart failure
were not significantly different. They did find that there was a higher rate of withdrawals
due to adverse events and tuberculosis reactivation, associated with the use of
biologics.
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The Cochrane review also found that certolizumab pegol was associated with a
significantly higher risk of serious infections compared to control treatment. The odds
ratio was 3.51, 95% CI (1.59, 7.79). The results of our meta-analysis, which looked at
only patients with inflammatory bowel disease, found that there was no difference in the
frequency of serious infections between anti-TNF-a and control groups. The risk ratio
was 1.00 with a 95% CI (0.71, 1.39) for the anti-TNF-a drugs compared to placebo
Also, no individual anti-TNF-a medications were found to be statistically different than
control groups with respect to the development of serious infections. However, the
individual risk ratio for certolizumab was 2.30, 95% CI (0.92, 578) The risk ratio
calculated for infliximab was 0.86, 95% CI (0.54, 1.37), adalimumab was 0.69, 95% CI
(0.34, 140), and CDP571 was 1.35, 95% CI (046, 4.00). This trend for certolizumab to
be associated with more serious infections is something that requires further
examination. If certolizumab causes more serious infections this would be a major
concern and might affect how this agent is prescribed. If all other adverse events are
comparable, agents with a lower risk of infection, especially serious infection, should be
prescribed first
The Cochrane review of all biologics found that infliximab was associated with a
statistically significant increased likelihood of withdrawal due to adverse effects
compared to control (OR 2.04, 95% CI 143 to 2.91). The other biologics were not
significantly different from control. Our analysis looked at this outcome and the overall
risk ratio for all anti-TNF-a agents was 0.87, 95% CI (0.73, 1.04). In subgroup analysis
there was no difference for infliximab and the risk ratio was 1.19, 95% CI (082, 172)
The findings are different but this can easily be explained by the fact that patients with
different conditions may have varying reasons for withdrawing from a study. The
Cochrane meta-analysis also included many more patients and thus had more statistical
power to detect a difference.
Overall, the results of the Cochrane review of biologics for all conditions were similar to
this review of anti-TNF-a agents used for inflammatory bowel disease: generally these
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agents are safe but prescribers must be vigilant and monitor for adverse events and
serious infections.
6.1.5 Biologic Agents used for Rheumatoid Arthritis
Rheumatoid arthritis is an inflammatory arthritis that affects 0.5% to 1.0% of adults in
Western countries (Kvien 2004). It results in joint inflammation and destruction which
leads to major decrements in quality of life (Odegard 2005) and disability (Yelin 2007).
There are similarities in the pathogenesis of rheumatoid arthritis and Crohn's disease.
Specifically, dysregulation of T-helper cell subsets and specific cytokines which
influence the development and perpetuation of systemic inflammation are involved in
the pathogenesis of inflammation in both these conditions
Biologic therapies are used for the treatment of rheumatoid arthritis. These agents
target either the down regulation of proinflammatory responses or the up regulation of
anti-inflammatory cytokine production. Several biologics are currently approved for the
treatment of rheumatoid arthritis in Canada. Their use has revolutionized the treatment
of this condition and they dramatically inhibit the progression of joint damage. These
medications include anti-TNF-a agents, anti-interleukin-1 therapy, anti-CD28 therapy
and anti-B-cell therapy. Biologics are generally recommended for patients with
rheumatoid arthritis who have a suboptimal response or intolerance to traditional anti-
rheumatic drugs: the treatment of CD also follows a similar step up process.
Rheumatologists share the same concerns as gastroenterologists with respect to the
adverse event profiles of these agents. One of the first systematic reviews to address
the topic of safety and biologics in the treatment of rheumatoid arthritis was conducted
by Bongartz 2006. His group assessed the extent to which anti-TNF-a therapies
increased the risk of serious infections and malignancies in patients with rheumatoid
arthritis. They conducted a meta-analysis to derive estimates of these adverse events.
This group analyzed nine trials and obtained data on 3493 patients who received
infliximab or adalimumab and 1512 patients who received placebo. The pooled odds
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ratio for malignancy was 3.3, 95% CI (1.2, 9.1) and for serious infection was 2.0, 95%
CI (1.3, 3.1). Another meta-analysis was conducted to compare the benefits and safety
of 6 biologics (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab) in
patients with rheumatoid arthritis (Singh 2009). They found that withdrawals related to
adverse events were significantly higher among patients taking adalimumab, OR 1.54,
95% CI (1.12, 2.12), anakinra OR 1.67, 95% CI (122, 2.29) and infliximab OR 2.21,
95% CI (1.28, 3.82) compared to placebo. The other agents studied etanercept,
rituximab and abatacept did not result in increased withdrawal compared to placebo
Likewise, the results for anti-TNF-a agents used to treat CD found that none of these
agents resulted in increased withdrawals compared to placebo. The risk ratio from
Crohn's studies for withdrawal due to adverse events was 0.87,95% CI (0.73, 104)
This group's analysis also compared biologics and withdrawal from therapy. They found
significantly lower rates of withdrawals because of adverse events with etanercept than
with adalimumab, anakinra or infliximab (Lee 2008). Unfortunately, etanercept was not
an effective treatment for inflammatory bowel disease.
Another systematic review was conducted that analyzed randomized clinical trials which
compared intravenous administration of infliximab to placebo in patients with
rheumatoid arthritis (Wiens 2009). This review also included a meta-analysis to assess
the efficacy and the safety of infliximab use and withdrawals due to adverse events or
lack of efficacy. Seven trials comprising 2,129 patients met the inclusion criteria. The
following results were found:
1. serious adverse events: relative risk 1.12, 95% CI (0.90, 1.41)
2. withdrawals due to adverse events: relative risk 2.05, 95% CI (1.33, 316)
3. deaths: relative risk 0.71, 95% CI (0.11,4.85)
4. malignancy: relative risk 1.64, 95% CI (0.30, 8.89)
5. serious infections: relative risk 0.96, 95% CI (0.39, 238)
6. infusion reactions: relative risk 1.97, 95% CI (1.12, 3.45)
7. infection: relative risk 1.21, 95% CI (099, 1.49)
8. any adverse events: relative risk 0.83, 95% CI (0.64, 1.08).
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Results are available for the first six variables from our meta-analysis. The ratios were
ascertained from subgroup analysis regarding infliximab for the treatment of
inflammatory bowel disease:
1. serious adverse events: relative risk 0.77, 95% CI (0.64, 0.93)
2. withdrawals due to adverse events: relative risk 1.19,95% CI (0.82,1.72)
3. deaths: relative risk 1.99, 95% CI (0.44, 8.99)
4. malignancy: relative risk 1.05, 95% CI (0.32, 3.41)
5. serious infections: relative risk 0.86, 95% CI (0.54, 1.37)
6. infusion reactions: relative risk 1.47, 95% CI (1.11, 1.93).
These results are very similar and it is reassuring to see that there is consistency in the
adverse event profile of infliximab for two different medical conditions.
A similar review was conducted regarding the use of adalimumab for the treatment of
rheumatoid arthritis (Wiens 2010). This review also included a meta-analysis to assess
the efficacy and the safety of adalimumab use and withdrawals due to adverse events
or lack of efficacy. Eight studies met the inclusion criteria, comprising 2,692 patients
This meta-analysis of safety revealed the following results:
1. serious adverse events: relative risk 0.98,95% CI (0.67, 1.43)
2. withdrawals due to adverse events: relative risk 1.56, 95% CI (1.04, 2.35)
3. deaths: relative risk 2.52, 95% CI (0.72, 8.86)
4. malignancy: relative risk 0.55, 95% CI (0.14, 2.11)
5. serious infections: relative risk 2.22, 95% CI (0.83, 5.99).
The corresponding results for adalimumab from our meta-analysis are:
1. serious adverse events: relative risk 0.77,95% CI (0.64, 0.93)
2. withdrawals due to adverse events: relative risk 0.50, 95% CI (0.33, 0.75)
3. deaths: relative risk 1.99, 95% CI (0.44, 8.99)
4. malignancy: relative risk 0.08,95% CI (0.01,0.71)
5. serious infections: relative risk 0.69, 95% CI (0.34, 1.40).
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These results were similar with the exception of withdrawal due to adverse events. As
mentioned earlier there was an aberrancy noted in the withdrawals in the adalimumab
trials because of the high number of withdrawals due to a flare up of Crohn's disease.
6.1.6 Biologic Agents used for Psoriasis
Psoriasis is one of the most common immune-mediated disorders affecting about 2 to
3% of the general population (Griffiths 2007). It is a chronic incurable autoimmune skin
condition that has remarkable costs because it causes substantial problems in everyday
life, work limitations and productivity loss (de Korte 2004; Javitz 2002; Naldi 2004;
Schmitt 2006; Stern 2004). Several recent studies have suggested that patients with
psoriasis have an increased risk for cardiovascular disease, depressive illness, liver
disease and a decreased life expectancy (Gelfand 2006; Gelfand 2007; Kremers 2007;
Mallbris 2004; Schmitt 2007). T-cells and TNF-a playa central role in the pathogenesis
of psoriasis. Currently, three biologic anti-TNF-a agents: infliximab (Chaudhari 2001),
etanercept (Leonardi 2003), and adalimumab (Menter 2008), and two T-cell agents:
efalizumab (Gordon 2003) and alefacept (Ellis 2001) are approved for chronic plaque
psoriasis.
Schmitt 2008 conducted a meta-analysis of all published randomized controlled trials of
biologic and nonbiologic systemic treatments approved for moderate to severe plaque
psoriasis to determine their comparative efficacy and tolerability. Overall, 24
randomized trials including 9,384 patients with chronic plaque psoriasis met the
inclusion criteria. This group found similar incidence rates of withdrawals due to adverse
events for all drugs used to treat psoriasis: 1.3% for infliximab, 1.2% for cyclosporine
and efalizumab, 0.5% for etanercept and 0.3% for adalimumab. With respect to
reactions the pooled monthly incidence rate of infusion reactions was 2.6% for infliximab
while the incidence rate of injection site reactions was 4.8% in patients treated with
etanercept. The most commonly reported infections were upper respiratory tract with a
monthly incidence rate of 1.8% in patients treated with adalimumab (Menter 2008).
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A German group conducted a similar systematic review and meta-analysis of all
randomized controlled trials in which biologics for the treatment of psoriasis were
examined (Zhang 2009). Secondary endpoints of this analysis were the monthly
incidences of study withdrawals and adverse events. They obtained data on 8,057
patients and found that the monthly incidence rates of withdrawals due to adverse
events were 1.2% for infliximab, 0.5% for etanercept, 1.0% for efalizumab, and 0.5% for
adalimumab They did not report on other adverse events.
Psoriatic arthritis is a seronegative inflammatory arthropathy that complicates about
30% of patients with psoriasis. It is also treated with disease-modifying anti-rheumatic
drugs (OMAROs) as well as biological agents. A meta-analysis of 18 studies assessing
various agents used to treat psoriatic arthritis was conducted (Ravindran 2008). In total
11 studies assessing OMARO monotherapy, one study assessed OMARO
combinations, five studied anti-TNF-a agents and one studied another biologic agent,
alefacept. Overall anti-TNF-a agents showed the largest treatment effect sizes and they
had the best efficacy-to-toxicity ratio. Toxicity leading to withdrawal was more common
among the other agents studied: leflunomide, gold salts and sulfasalazine.
Overall, the results for psoriasis and psoriatic arthritis are similar to the results found for
IBO. In both conditions the most commonly reported adverse events were infections.
Respiratory tract infections were by far the most frequently seen infection.
6.1.7Infliximab Safety in Outpatients
Ouscharme et al recently addressed the issue of the safety of infliximab administration
in community clinics outside the hospital environment. Most publications describing
acute adverse drug reactions have been limited to the hospital environment or within the
confines of clinical trials (Ouscharme 2010). Since these patients are preselected and
do not represent the full spectrum of patients receiving infliximab the risk of adverse
events and infusion reactions is likely not the same in the community setting.
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Duscharme's goal was to evaluate the safety of infliximab across all types of patients in
a community setting. This group conducted a retrospective chart review on the infusion
reaction rate seen in patients treated with infliximab in community infusion clinics from
December 1, 2006 to April 15, 2008 throughout Ontario. Results were obtained from
multiple infusion clinics across Ontario. These clinics all followed standardized infliximab
infusion and monitoring protocols and these protocols were in place for more than six
years. The patients were followed by community specialists and were diagnosed with
UC, Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis or uveitis.
On the day of the infusion patients were initially seen by a nurse and underwent an
assessment prior to initiating infliximab. During the infusion, vital signs were monitored
and recorded every 30 minutes and then monitored for one hour post infusion. The
patients were asked to seek medical attention should any adverse event occur after
discharge. A total of 3161 patients received 20,976 infliximab infusions during the time
frame analyzed. Acute adverse drug reactions that occurred during the infusion or within
twenty four hours of the infusion were included. Most reactions that occurred after this
would have been seen by private family physicians or in the emergency room and
unfortunately were not accessible
Five hundred twenty-four acute adverse drug reactions occurred in 353 patients
(11.2%). Two hundred sixty-three reactions were classified as mild (1.3% of all infusions
and 233 were moderate (1.1 % of all infusions). Twenty-eight reactions were severe
representing about 1 out of 1000 infusions. Seven patients required transfer to a
hospital emergency room but none were admitted. The group also noted that the
number of infusion reactions did not vary according to age or diagnosis
With respect to our meta-analysis, a subgroup analysis revealed that 160 out of 1125
patients who received infliximab (14.2%) had an infusion reaction. The majority of these
were mild reactions but some were delayed infusion reactions. It should also be noted
that 24 out of 689 patients receiving placebo (3.4%) developed an infusion reaction. The
risk of infusion reaction attributable to infliximab from the combined data of the clinical
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trials is 10.8%. This number is very similar to that found by Duscharme et al. This would
indicate that the risk of an infusion reaction in a real life setting is comparable to the
results of clinical trials and meta-analyses.
6.1.8 Adalimumab Safety in Outpatients
Adalimumab has been studied for the treatment of rheumatoid arthritis, psoriatic
arthritis, ankylosing spondylitis, Grohn's disease, psoriasis and juvenile idiopathic
arthritis. An analysis of 19,041 patients in 36 global clinical trials was carried out to
determine the safety of adalimumab, the stability of serious adverse event rates over
time and compare the safety of adalimumab in psoriatic arthritis, ankylosing spondylitis,
Grohn's disease, psoriasis and juvenile idiopathic arthritis within the context of the
established safety profile in rheumatoid arthritis (Burmester 2009). A secondary
outcome was an assessment of the number of malignancies and mortality rates
The results revealed that the cumulative serious adverse events rates from 2002, 2004,
2005 and 2006 were found to be comparable to 2007:
- serious infections (4.6-5.1 versus 4.7/100 patient-years)
- tuberculosis (0.22-0.28 versus 0.29/100 patient-years)
- lymphomas (0.10-0.21 versus 0.12/100 patient-years)
- demyelinating disease (0.05-0.08 versus 0.05/100 patient-years)
- lupus-like syndrome (0.05-0.10 versus 0.07/100 patient years).
Serious infections were the most commonly reported adverse event. It was interesting
to note that the greatest rates of serious infections were observed for patients with
rheumatoid arthritis and Grohn's disease. The most commonly reported serious
infections were pneumonia and abscess. These results are similar to the findings of our
meta-analysis where serious infections were the most commonly reported serious
adverse event.
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Tuberculosis was rare and rates were similar across all diseases. The most commonly
reported opportunistic infections were oral candidiasis, followed by six cases of
histoplasmosis; three cases of cytomegalovirus infections and two cases each of
coccidioidomycosis and nocardiosis. There was one case each of toxoplasmosis,
listeriosis, aspergilloma, Pneumocystis infection, esophageal candidiasis and candida
sepsis. These infections occurred in patients with CD and rheumatoid arthritis.
Opportunistic infections were infrequently reported among patients with other immune-
mediated inflammatory diseases. These data support our post marketing surveillance
data analysis which revealed that opportunistic infections occur in patients with Crohn's
disease. These infections were not reported to the same degree during randomized
trials and can be quite serious.
The adalimumab review also found the risk of malignancies was not increased when
compared with the general population. However risks associated with long-term use
were not evaluated. The review did find the number of cases of lymphoma in patients
with rheumatoid arthritis to be significantly greater than that expected for the general
population. However patients with rheumatoid arthritis have an inherent twofold
increased risk of developing lymphomas irrespective of therapy compared with the
general population (Baecklund 2006; Gridley 1993; Mellemkjaer 1996) Our meta-
analysis showed no increased risk of malignancy but this is a rare long term adverse
outcome that may manifest at a later date.
6.2 Temporal Comparison of Adverse Events
As part of this analysis the initial data from the Treat registry were combined with the
post marketing data and a pooled estimate was determined for four specific outcomes
death, malignancy, serious infections and tuberculosis. The meta-analysis determined
that the probability of death was 2 per 1000 patients. Based on post marketing data
combined with TREAT results this estimate increased to 7.7 and 17.2 based on the 1.7
and 5 year respectively. The five year data from the Treat registry found no difference
between patients treated with infliximab and those treated with other agents. It is no
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surprise that the results from the meta-analysis are much lower than either the 1.7 or 5
year data because the analysis is based on randomized trials that ranged in durations
from 4 to 56 weeks.
Likewise the data for the development of malignancy showed a temporal increase. The
results of the meta-analysis revealed 4.0 cases per 1000 patients and this increased to
a pooled estimate of 13.5 cases for the 1.7 year TREAT data and post marketing data.
The estimate increased further to 18.0 when the 5 year Treat data were included. It is
important to note that over time the risk of malignancy increases while patients are
taking anti-TNF-a drugs. However, once again the five year data from the Treat registry
shows that for patients with CO on other therapies this is also true. In fact other studies
have shown that patients with IBO are at an increased risk of malignancy even if no
medications are taken (Bernstein 2001).
From a clinicians perspective serious infections are always a major concern with
biologic use and are the most common serious adverse event. The combination of 5
year post marketing data showed the rate to be 72.1 per 1000 patients. The rate from
the meta-analysis was 24 and this is lower due to the short time frame of the included
studies. According to the TREAT data serious infections also occur frequently in
patients with CD treated with any pharmaceutical. In fact, Crohn's patients have a
higher baseline risk of infection than the general population.
Opportunistic infections can occur with the use of anti-TNF-a agents. The reactivation of
latent tuberculosis is a major complication with the use of these agents. Screening for
tuberculosis prior to initiating infliximab is currently the standard of care. The results of
this study found that the rate of development of tuberculosis did not increase over time
This means that patients who develop tuberculosis generally do so early in the course
of treatment with an anti-TNF-a agent. Also, patients who developed tuberculosis often
had a negative skin test and chest X-ray prior to commencing therapy. It should also be
noted that patients with positive skin tests who received adequate prophylaxis did not
develop tuberculosis.
48
The rate of development of TB was constant at approximately one per 1000 patients.
However this would still seem high in light of the fact screening for this condition is
carried out prior to starting therapy. It is well recognized that the use of tuberculin skin
testing for patients with CD and UC is controversial. This is due to the high rate of false-
negative results in patients receiving immunosuppressive treatment (Connell 2006).
Quantiferon is a new method for detecting latent tuberculosis. It is an interferon gamma
release assay that has a greater sensitivity and specificity for tuberculosis than
tuberculin skin testing Since these interferon-gamma release assays are more reliable
than tuberculin skin tests they are being utilized by some physicians prior to
commencing an anti-TNF-a agent (Bocchino 2008).
6.3 Post Marketing Surveillance in Canada
Before any drug can be marketed in Canada, efficacy and safety must be established.
Rigorous well designed clinical trials are required to generate these data. These trials
often have small numbers of patients, last for a short period of time and often include
highly selected participants who differ from those in a standard practice. The people in
these trials frequently do not have the co-morbidities which may exist in the population
the drug will eventually be prescribed to. The participants in trials may also be more
compliant and more likely to seek medical attention when adverse events arise.
Since all possible adverse events of a drug cannot be determined based on clinical
trials, it is essential that drugs continue to be investigated after they have entered the
market in order to ascertain long term safety and efficacy data. This post marketing
surveillance can further refine, confirm or deny the safety of a drug. However, post
marketing surveillance is only useful if it is carried out in a manner which allows
information to be obtained on large numbers of individuals who have a wide variety of
medical conditions. Concerns have been raised regarding the lack of an appropriate
process for evaluating newly approved pharmaceuticals and therapeutics. This is a
worldwide problem and also a major clinical concern in Canada (Laupacis 2003).
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One of the strengths of this analysis is that post marketing surveillance data were
included. A total of 16 different post marketing sources were reviewed. Most of the
reports were fairly large with a few hundred patients but the TREAT registry is a
substantial resource and contains information regarding 6290 patients. The most
interesting finding of the post marketing surveillance data was the number of reports of
opportunistic infections: one case of Listeria (Lichtenstein 2006), two cases of
Pneumocystis carini (Lichtenstein 2006, Ljung 2004), three cases of Aspergillus
infection (Armuzzi 2004; Miheller 2009; Ochsenkuhn 2008), one case of histoplasmosis
(Colombel 2004) and multiple cases of herpes zoster (Armuzzi 2004; Jarnerot 2005;
Miheller 2009; Ochsenkuhn 2008; Sands 2007; Seiderer 2004) and tuberculosis
(Miheller 2009). In contrast, no cases of opportunistic fungal infections were noted
during the clinical trials. These fungal infections can be quite serious and even fatal
There is a paucity of data regarding the risk of fungal infections during anti-TNF-a
therapy. The Mayo clinic has reviewed this topic and found that the majority of patients
(98%) who experienced fungal infections were also on concomitant immunosuppressive
therapy (Tsiodras 2008). It was also noted that the risk of these infections dramatically
increases when anti-TNF-a therapy is combined with corticosteroids or thiopurine
therapy (Toruner 2008). The most common pathogens were those causing
histoplasmosis (30%), candidiasis (23%), and aspergillosis (23%) Overall the Mayo
clinic has also reported that the risk of opportunistic infections in ISO patients treated
with infliximab to be 0.3%. It is noteworthy that invasive fungal infections were not noted
during the clinical trials but were detected by post marketing surveillance.
6.3.1 Improving Post Marketing Surveillance
Post marketing information can be gathered in various ways but usually it is obtained
from administrative databases, patient registries, surveys or reports from clinicians or
patients. However problems exist with each of these methods. These limitations include
under-reporting, incomplete data, poor quality data and difficulty demonstrating a causal
relationship between an exposure and an adverse event Regulatory authorities in
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Canada have expressed a vital need for pharmacoepidemiological data on long-term
efficacy, safety, and cost-effectiveness of new drugs in relation to the standard of care
(Barr 2004).
Spontaneous reporting systems have been created by various regulatory agencies such
as Health Canada and the Food and Drug Administration in the United States. These
have become the primary method of collecting post marketing information on drug
safety. The purpose of these reporting systems is the early detection of rare and serious
drug reactions. It allows physicians, pharmacists and patients to report suspected
reactions (van Grootheest 2004a, van Grootheest 2004b, van Grootheest 2005). The
main problem with this approach is the potential for selective reporting and
underreporting (Eland 2009). In one review article the magnitude of underreporting in
spontaneous reporting systems was determined to be more than 94% (Hazell 2006)
Chronic underreporting can lead to the false conclusion that risk is absent. Selective
reporting of risks may also give a false impression of a risk that does not exist.
Various approaches have been devised in an attempt to improve post marketing
surveillance for biologics. In Alberta, the Rheumatoid Arthritis Pharmacovigilance
Program and Outcomes Research in Therapeutics (RAPPORT) Team, has developed a
registry to assess the outcomes of biological therapies used in patients with rheumatoid
arthritis (Barr 2004). This team has developed a systematic approach to collecting data
on the effectiveness, adverse events and cost-effectiveness of biologics for the
treatment of rheumatoid arthritis in Alberta. It is a collaborative venture between
academia, government payers, and industry.
All patients in Alberta using biologic therapies to treat rheumatoid arthritis and who wish
to receive public coverage are required to become a part of the RAPPORT registry.
Data collected includes demographics, co-morbid conditions, quality of life measures,
measures of health care resource use, and medication history. This registry allows for
the surveillance of the effectiveness of therapy and adverse events. The program is
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funded by industry but is administered by government and operates at arms length from
industry.
A similar undertaking could be used to monitor patients with IBO The information
gathered would be of greater value if such an endeavor were conducted on a national
level. This would further expand the pool of participants allowing very rare events to be
captured. An even greater initiative could be to include all patients on anti-TNF-a
agents, irrespective of diagnosis. Since Canada has a relatively small population, a
uniform medical system and one of the highest rates of IBO in the world, a nationwide
registry of IBO patients on biologics could enable us to become an international leader
in pharmacosurveillance. Similar initiatives have occurred in Sweden (van Vollenhoven
2003), Spain (Gomez-Reino 2003), and the United Kingdom (Silman 2003) for biologic
use in patients with rheumatoid arthritis.
Provincial drug plans, hospital databases and third party payer administered programs
are other rich sources of data. These resources could be used to provide details on
patients who have IBO. Drug databases could be cross referenced with the diagnosis to
determine who is at risk and who should be monitored. These patients could then be
observed closely for the development of adverse events. Unfortunately, despite the
existence of these drug databases they have been underutilized for this purpose. One
other potential problem is variability between provinces in terms of coverage and data
collected. This means that pooling of this information could be difficult.
Patient registries are sometimes implemented by manufacturers to monitor certain
medications. These databases offer the opportunity to monitor patients for serious
adverse drug reactions and may help reduce exposure to high-risk drugs. Access to the
data contained in such registries is often limited by the pharmaceutical companies
Timely access may be difficult and opportunities for replication by others can be
restricted.
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As mentioned earlier, the TREAT registry has been established for patients with CD
(Lichtenstein 2006). It is a prospective, observational, multicenter endeavour that has
focused on clinical, economic, and adverse events associated with the treatment of
Crohn's disease. Physicians manage patients as they would under normal practice
conditions and there is no predefined schedule of visits or medical procedures. Data
regarding disease severity, medication use and adverse events were collected on a
semi-annual basis by physicians (Silman 2003).
Currently there is no clear consensus on the 'best' way to carry out post marketing
surveillance in Canada. The optimal strategy would appear to involve obtaining
population-level data on a national level and allowing relatively open access so that it
could be easily monitored for validity and reliability. It is critical that post marketing
surveillance meets the following criteria:
1. scientific rigor in evaluating clinically-meaningful outcomes;
2. collection of population-level data;
3. timely and relatively easy access to data;
4. independent assessment;
5. sustainable research groups with relevant expertise;
6. affordability;
7. transparency (Carleton 2005).
In the future post marketing surveillance must be able to identify new safety issues
without delay. If this does not happen patients' confidence in drugs will be eroded as
serious adverse events occur and are publicized. As we move forward, methods to
identify patients at risk of developing an adverse drug reaction need to be developed.
Any future endeavours need to use patients as a source of information. This approach
would be consistent with the growing trend of patient involvement in drug safety
6.3.2 Monitoring for Adverse Events
There is considerable debate regarding the appropriate procedure for determining a
reliable estimate for the risk of adverse effects (Ioannidis 2006). A diverse range of
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study designs including randomized controlled trials, cohort or case-control studies can
be used to record adverse events. Randomized controlled trials yield unbiased outcome
estimates of treatment effect but due to the short timeframe of these studies adverse
event data can be inaccurate (Levine 1994; Meade 1997; Papanikolaou 2006). Many
reviews have found that randomized trials fail to provide adequate adverse event data
and the information provided is often poor (Cuervo 2003; Ethgen 2005; loannidis 2001a;
loannidis 2006; loannidis 1998; Nuovo 2007; Papanikolaou 2004). These trials are
designed and powered to explore efficacy not adverse events which are less likely to
occur than treatment effect (Aagaard 2009; Clarke 2006; Henry 1999; Hughes 2007;
Kaufman 2000; Lee 2008; Vandenbroucke 2004). Also, randomized trials often have
rigid exclusion criteria that may exclude patients at high risk of adverse effects and
those with potential drug interactions (Ahmad 2003; Chou 2005; Gutterman 2004;
Hyrich 2005; Mittmann 1999; Ravaud 2005; Vandenbroucke 2006).
Post marketing surveillance is another strategy for the detection of adverse events. The
data are usually collected from observational or retrospective studies, but these sources
are afflicted by an increased risk of bias and confounding. Nevertheless, observational
data may be the only available source of information for particular adverse effects
(Jacob 2000; Psaty 1999; Skegg 2001). Like randomized controlled trials these
observational studies are another potential source of adverse event data to be used in a
meta-analysis. However there is the potential for discrepancy between the pooled
estimates depending on what type of study is used.
It is well recognized that differences in treatment effect between randomized trials and
observational studies exist (Britton 1998; Concato 2000; loannidis 2001b; Oliver 2010;
Shikata 2006). Likewise there are many examples of both agreement and disagreement
in the reported risk of adverse events between randomized controlled trials and
observational studies (Berlin 1999; Jick 1998; McPherson 2004; Ray 2003) There are
many reasons why the results between pooled observational data and meta-analysis
could differ. Randomized controlled trials have a strict methodological evaluation
compared to observational cohorts. Randomized controlled trials may record a higher
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incidence of adverse effects because of closer monitoring of patients and more
thorough recording. Observational studies are longer and more likely to detect rare
adverse outcomes. Trials are also more likely to be conducted in line with regulatory
requirements and this will affect the recording of adverse events (Ofman 2002).
Depending on the source of the data the conclusions of the meta-analysis could be
different.
There is considerable debate and controversy as to the relative merits of using
randomized controlled trial data as opposed to observational data from systematic
reviews to determine the overall rate of adverse events. One group actually examined
the estimates of harm from meta-analyses of randomized study designs and compared
them to estimates from meta-analyses of similar observational studies. This meta-
analysis of meta-analyses aimed to assess the level of agreement or disagreement in
the estimates of harm derived from meta-analysis of RCTs as compared to meta-
analysis of observational studies (Golder 2011). This group carried out searches in ten
databases in addition to reference checking, contacting experts, citation searches, and
hand-searching key journals, conference proceedings, and web sites to identify studies
A pooled relative measure of an adverse effect (odds ratio or risk ratio) from
randomized trials was directly compared with the pooled estimate for the same adverse
effect arising from observational studies. The pooled ratio of odds ratios of RCTs
compared to observational studies was estimated to be 1.03, 95% CI (0.93, 1.15). In
terms of statistical significance, for 37 of 58 studies (64%), the results agreed. Thus
64% of the time both studies showing a significant increase, significant decrease or no
significant difference. This evidence indicates that systematic reviews of adverse effects
should not be restricted to specific study types. Their conclusion was that there was no
difference on average in the risk estimate of adverse effects of an intervention derived
from a meta-analysis of randomized trials versus a meta-analysis of observational
studies.
55
6.4 Limitations of this Study
As with any meta-analysis, these results need to be interpreted with caution and there
are limitations to this data. Clinical trials might contain patients which are not
representative of clinical practice. Also many of these trials are short in duration
ranging from 4 to 56 weeks whereas in clinical practice most patients will be on these
drugs for many years. Follow-up might not be long enough for some rare long term
adverse events to be detected. As well, some uncommon severe complications might
only occur in patients receiving combination therapy with both anti-TNF-a and
immunosuppressive agents.
Publication bias was assessed. This form of bias usually refers to the non-publication of
trials which show no evidence of efficacy. The funnel plot was symmetrical suggesting
the absence of publication bias. However, given that the purpose of this meta-analysis
was to assess for adverse events this may not be an appropriate measure. From our
perspective, publication bias would be important if rare side effects were not reported.
This is certainly a concern from the standpoint of our review and was addressed by a
post-marketing review. By conducting this we did find that the randomized trials were
not long enough to capture serious rare adverse events such as invasive fungal
infections.
The data presented regarding the pooled estimates of the post marketing data has a
number of limitations as well. When comparing the pooled results from different
observational study designs it is important to consider confounding factors. For
instance, different medications were prescribed, some patients did not receive a
complete induction therapy, maintenance therapy was observed for different durations,
concomitant medications differed, as did demographics. Based on this it might be
expected that the magnitude of any adverse events recorded would be significantly
different. However this was not the case. Slight increases were seen as patients were
on these agents long term. This is expected since the longer you are on any
pharmaceutical the more likely you are to develop an adverse outcome.
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Chapter 7. Conclusion
The results of this meta-analysis demonstrate that anti-TNF-a agents are safe for
patients with inflammatory bowel disease not responding to conventional treatment with
steroids, mesalamine or immunosuppressants. However, these patients must be
monitored closely for the development of infections, malignancy and other autoimmune
conditions. From this review, it is clear that rigorous, independent and timely post
marketing surveillance must continue to be carried out regarding biological agents since
certain extremely rare side effects may not yet be detected. Overall, the information in
this analysis will serve to reassure many clinicians and patients that anti-TNF-a agents
are safe in patients who have failed standard medical therapy. However, serious
adverse events can occur and need to be monitored.
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Events Total Events Total Wei hi
Risk Ratio
M-H Fixed, 95%CI
Risk Ratio
M-H,Fixed 95'1oCI
365
24
57
63
37
138
83
78.,
1.3.1Inlhimab
Hanauer 2002
Jarnerot2005
Lernann2006
Presenl1999
RlIIgeerts1999
Sands 2004
largan 1997
Subtolal(95%CI)
Total events 5
Heterogeneity: Chi' ~ 1 76.df= 2(P = 041), 1'=0%
TestforoveralieflectZ=0.90(P=037)
188
21
56
31
36 39.4%
144 127%
25
501
3.431018.6602)
Noteslimable
Not estimable
Not estimable
0321001.7.,'1
0221025.107681
Notesttm,lble
1.99 [0.44. 8.99J
1.3.2 Adalimumab
Colombel2007 517 261 NOleslimable
Hanauer 2006 225 74 Nolestomable
Sandborn2007a 159 166 NOlestimable
Sandborn2007b 37 18 Not estimable
Subtotal (95% CI) 938 519 Not estimable
Totalevenls
HelerogeneilyNotapplicable
Tesl for overall eflect: Nolapplicable
1.3.3CertolizlImab
Sandborn2007c 331 329 2.98[012.72931
Schreiber 2005 219 73 Not estimable
Schreiber 2007 216 212 Nolestlnlable
Winter 2004 68 24 Not estimable
SulJtotal (95% CI) 834 638 2.9810.12. 72.93J
Total events
Heterogeneity: Nolappllcable
Teslforoverallelfect:Z=0.67 (P= 0.50)
1.3.4CDP571
Feagan 2005 39 32
Feagan 2006 181 68 1.4710.06,35.651
Sandborn2001a 111 56 Noteslimable
Sandborn 2004 263 133 Not estimable
Stacklg97 21 10 Not estimable
Subtotal (95%CI) 615 321 1.47[0.06,35.65)
Total events
Helerogeneily:Nolapphcable
Testforoveralieflect:Z=024(P=0.61)
1.3.5 Etanercept
Sandborn2001b 23 0 20 Noleslimilble
subtolal(95%CI) 23 20 Not estimable
Total events
Heterogeneity' NOlilpphcable
Test for overall effect Not applicable
1.3.60nercept
Rutgeerts2006 170 0 37 Noleslimablc
Subtotal (95% CI) 170 37 Not estimable
Tolalevenls
Helerogeneity'Nolilpplicable
Tesl for overall eflect Not applicable
Tolal(95%CI)
Tolalevenls 7
Helerogeneity:Chi'=1.86.df=4(P=0.76):I'=O%
Teslforoveralieffect:Z=1.11(P=027)
Test for subqroup difterences: Chi' = 0.10. dl = 2 (P ~ 0.951.1' = 0%
Figure 4. Deaths
001 01
F;lVOlJrse>"pl'r1nlrofltA!
TNF-alphaantagonist Placebo
Events Total Events Total Wei ht
Risk Ratio
M-H,Fixed,95%CI
Risk Ratio
M-H,Fixed,95%CI
385
57
63
37
484
138
83
1247
1.4.1Infliximab
Hanauer 2002
Lemann2006
Present 1999
Rutgeerts1999
Rutgeerts2005
Sands 2004
Targan1997
Subtotal (95% CI)
Total events 8
Helerogeneily:Chi'=0.88.df=2(P=0.65);F=0%
Testforoveralieffect:Z=0.08(P=0.94)
ColombeI 2007 517
Hanauer 2006 225
Sandborn2007b 258
Subtotal (95% CI) 1000
188
56
31
36 10.7%
244 9.4%
144
25
724
261
74
18 19.7%
353 33.7%
098[0.18,528]
Not estimable
Not estimable
03210.01,7.711
2.02[0.23,17941
Noleslimable
Nolestimable
1.05[0.32,3.41]
0.17[001,4.121
Noteslimable
002[000,0581---
0.08[0.01,O.711~
1.4.3Certolizumab
Sandborn2007c 331
Schreiber 2007 216
Subtotal (95%CI) 547
Tolalevents
Heterogeneity: Not applicable
Testforoveralieffecl:Z=0.01(P=1.00)
1.4.4CDP571
Feagan 2005 39
Feagan 2006 181
Sandborn2001a 111
Sandborn 2004 263
Stack 1997 21
Subtotal (95%CI) 615
TOlalevenls 2
Heterogeneily:Chi'=0.55.df=1(P=0.46):I'=0%
Teslforoveralieffect:Z=0.08(P=0.94)
329
212
541
32
88
58
133
10
321
0.991014,7.01)
Not estimable
0.99[0.14,7.01)
2.48(0.10. 58.76J
Not estimable
NOlestimable
051 [003,8.02)
Noteslimable
1.08[0.16.7.50]
1.4.5 Etanercept
Sandborn2001b
Subtotal (95% CI)
Total events
Helerogeneity:Notapplicable
Test for overall effect: Nolapplicable
1.4.60nercept
Subtotal (95% CI)
23
23
o 20
20
Not estimable
Not estimable
Total (95% CI)
Total events 12
Helerogenelty·Chl'=7.15.df=7(P=0.41).I'=2%
Testforoveralieffect:Z=0.85(P=0.39)
TeslforsubQroupd,fferences:Chi'=4.56.df=3(P=0.211.1'=34.2%
Figure 5. Malignancies
0.72[0.34,1.53)
0.01 01 1 10 100
FavoursexpeJllTlental FavollfsGUlltrul
TNF.alphaantagonist Placebo Risk Ratio Risk Ratio
Events Total Events Total M-H Fixed.95%CI M.H,Fixed,95%CI
14 385 188 085[0.36.200)
24 21 02910.03.260)
57 56 0.4910.05.5.271
8 63 31 394[0.51.30.091
0 23 19 0.28[0.01.6.451
0 37 36 Not estimable
16 484 244 1.34[0.53.3.39)
138 144 0.46[015.147)
83 25 030[002.4641
1294 764 0.8610.54.1.37J
1.5.2 Adalimumab
Colombel2007 517 261
Hanauer 2006 225 74
Sandborn2007a 159 166
Sandborn2007b 258 18
SlIbtolal (95% CI) 1159 519
331 329
219 73
216 212
68 24
834 638
1.5.4CDP571
Feagan 2005 39 32
~:~~~:r~oggol a 181 8858
Sandbom2004 263 133
Stack 1997 21 10
SlIbtolal(95%CI) 615 321
1.5.5 Etanercept
Sandborn2001b 23 0 20 Nolestim~ble
SlIbtotal (95% CI) 23 20 Not estimable
170 0 37 Notesllm~ble
37 Not estimable
Figure 6. Serious Infections
TNF-alphaantagonist Placebo Risk Ratio
Stud orSub rou Events Total Events Total Wei ht M-H,Fixed,95%CI
1.6.1Infiiximab
Hanauer 2002 385 188 147[0.06.35891
Rutgeerts2005 484 244 1.52[0.06.37061
Subtotal (95%CI) 869 432 1.49[0.16.14.30]
Tolalevents 2
Helerogeneily:Chi'=O.OO.df= 1 (P = 0.99); 1'=0%
Teslforoveralleffecl:Z=0.35(P=0.73)
Colombel2007
Hanauer 2006
Subtolal (95% CI)
Tolalevenls
Helerogeneily:Notapplicable
Testforoveralleffecl:Notapplicable
517
225
742
261
74
335
Noteslimable
Not estimable
Not estimable
1.6.3Certolizumab
Schreiber 2007
Winter 2004
Subtotal (95%CI)
TOlalevenls
Heterogeneity: Not applicable
TestforoveralleffectZ=0.66(P=0.51)
1.6.4CDP571
Feagan 2005
Feagan 2006
Sandborn 2004
Sublotal(95%CI)
Tolalevents
Heterogeneity; Not applicable
Testforoveralleffecl:Nolapplicable
1.6.5 Etanercept
Subtotal (95% CI)
Total events
Heterogeneily:Notapplicable
Testforoveralleffecl:Notapplicable
1.6.60nercept
Subtotal (95% CI)
Total evenIS
Helerogenelty.Nolapplicable
Teslforoveralleffecl:Notapplicable
216 212 2.94[0.12.71.881
68 24 Noteslimable
284 236 2.94[0.12,71.88]
39 32 Noteslimable
181 88 Noleslimable
263 133 Not estimable
483 253 Not estimable
Total (95% CI)
Tolalevenls 3
Helerogeneity:Chi'=0.12.df=2(P= 0.94); 1'=0%
Teslforoveralleffecl: Z=0.69(P =0.49)
Teslforsuboroupdifferences:Chi'=0.12.df= 1 fP=0.73).I'=0%
Figure 7. Tuberculosis
1.89[0.31. 11.69J
0.01 0.1 1 10 100
Favoursexpenmental Favollrscontrol
TNF-alphaantagonist Placebo Risk Ratio
Stud orSub rou Events Total Events Total Wei ht M-H,Fixed,95%CI
1,7.1Infliximab
Present 1999 63 31 150[0.06,35.80)
Rutgeerts2005 484 244 8,59[0.50, 148.17J
Subtotal (95% CI) 547 275 5.04[0.65,39.08]
Total events 9
Heterogeneity:Chi'=0.69,df=1(P=OAO);I'=0%
Testforoveralleffect:Z=1.55(P=0.12)
1.7,2 Adalimumab
Colombel2007 517
Hanauer 2006 225
Subtotal (95% CI) 742
Total events 3
Heterogeneity:Chi'=0,17,df=1(P=0.68);1'=0%
TestforoveralieffecI:Z=0.09(P=0.93)
261
74
335
152[0.06,37121
0.66[0.06,7,15)
0,92[0.14,6.04)
1.7.3Certolizumab
Schreiber 2007
Subtotal (95% Cf)
Tolalevents
Helerogeneity:Notapplicable
Testforoveralieffect:Z=0.66(P=0,51)
1.7.4CDP571
Fea9an2005
Feagan 2006
Subtotal (95% CI)
Tolalevents
Helerogeneity:Notapplicable
Test for overall effect: Not applicable
1.7,5 Etanercept
Subtotal (95% CI)
Tolalevenls
Heterogeneily:Nolapplicable
Tesl for overall eflecl: Not applicable
1,7,60nercept
Subtotal (95%CI)
Total events
Heterogeneity: Not applicable
Teslroroveralieffect:Notapplicable
216 0 212 12.6% 2.94[0.12,71.88)
216 212 12.6% 2.94[0.12,71.88)
39 32 Not estimable
181 88 Not estimable
220 120 Not estimable
Total (95%CI)
Tolalevenls 13
Heterogeneity:Chi'=2.15,df=4(P=0.71);I'=0%
Testforoveralieffect:Z=1.50(P=0.13)
TestforsubQrOuDdifferences:Chi'=1A8,df=2(P=OA8),I'=0%
Figure 8. Pneumonia
254[0.75,8.59]
0.01 0.1 1 10 100
Favours experimental Favours control
TNF-alphaantagonist Placebo
Events Total Events Total Wei ht
Risk Ratio
M-H,Fixed,95%CI
Risk Ratio
M·H,Fixed,95%CI
Tolalcvenls 28
Helerogeneily:Chi'=2,20,df=3(P=0.53):I'=0%
Teslforoveralielfect.Z=O.64(P=052)
0.98[0.06,15,32)
3.44[0.44,26.77)
0.76[0,13,4,50)
0.71[0.40,1,25]
0.85[0,51,1,41J
261 13.0% 0.811027,2.44J
74 1.5% 100[0.04,24181
166 6.7% 0,15[0,01,2861
501 21,2% 0.61[0.24,1.58)
329 5.9% 1.99[0.50,7.88J
212 2.0% 2.94[0,31,28.08)
24 1.4% 109[0,05,25,82)
565 9,3% 2.05[0,69,6.12J
32 5.4% 017[001,3321
88 1.3% 3.42(0.18,65551
58 5.1% 1,31[0.26,6531
178 11,8% 1,02[0.33,3.18)
1 57 1 56 2.0%
7 63 1 31 2.6%
3 484 2 244 5.2%
17 138 25 144 47.9%
742 475 57.7%
1,8,3Certolizumab
Sandborn2007c 331
Schreiber 2007 216
Winler2004 68
Subtotal (95%CI) 615
Total events 10
Helerogeneily:Chi'=O,26,df= 2(P =0,88): 1'=0%
Testforoveralielfect:Z=1.29(P=0,20)
1.8.4COP571
Feagan 2005 39
Feagan 2006 181
Sandborn2001a 111
Subtotal (95% CI) 331
Tolalevents 8
Helerogeneity·Chi'=2.15,df=2(P=0.34):I'=7%
Tesl lor overall effect: Z=0.04 (P =0.97)
Colombel2007 517
Hanauer 2006 225
Sandborn2007a 159
Subtotal (95%CI) 901
Tolalevents 9
Heterogeneity:Chi'=1.21,df=2(P=0,55):I'=0%
Testforoveralielfect:Z=1.01(P=0.31)
1.8.1Infliximab
Lemann2006
Presenl1999
Rutgeerts2005
Sands 2004
Subtotal (95%CI)
1.8.5 Etanercept
Subtotal(95%CI)
TOlalevenls
Helerogeneity:Notapplicable
Test for overall effect: Nolapplicable
1,8,60nercept
Subtotal (95% CI)
Tolalevcnls
Helerogeneity:Notapplicable
Test for overall effect· Nolapplicable
Totaf (95% CI)
Tolalevents 55
Helerogencily' Chi' =8.40,df= 12(P=0.75):I'=0%
Tesl for overall effect: Z=0,37(P=0.71)
TeslforsubqrouPdifferences:Chi'=2.91,df=3(P=0.41l.1'=0%
0.93[0,63,1.37]
0,01 0.1 1 10 100
FavoursexpCflmental FClVoufsconlrol
Figure 9. Abscess
TNF-alphaantagonist Placebo
Events Total Events Total Wei ht
Risk Ratio
M-H,Fixed,95%CI
Risk Ralio
M-H, Fixed,95%CI
2301 140,3761
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295[012.70871
292[0.12.6943)
1211076,1911
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1.13.1Infliximab
Hanauer 2002
Jarnero12005
Lemann2006
Rulgeertsl\J99
Rutgeerts2005
Sands 2004
Subtotal (95% CI)
Total events 160
Helerogeneity:Chi'=6.88.df=5(P=0.23):F=27%
Testforoveralleffect·Z=2.70(P=0.007)
1.13.2 Adalimumab
Subtotal (95% CI)
Totalevenls
Heterogeneity' Not applicable
Test for overall effeCI: Nolapplicable
1.13.3Certolizumab
Winter 2004
Sllblolal (95% CI)
Tolalevenls
Helerogeneily'Notapplicable
Test for overall effect. Not applicable
68
68
o 24
24
Noteslimable
Not estimable
Feagan 2005 5 39 3 32 2.6% 1.37 10.35,5291 -I---
Feagan 2006 39 181 13 88 13.6% 146(0.82,2.591 ~
Sandborn2001a 13 111 4 58 4.1% 1.70(0.58,4.971 -~
Sandborn 2004 54 263 14 133 14.4% 1.95[1.13,3.381
Stack1g97 5 21 4 10 4.2% 0.60[0.20,1.75] ~
Sublotal (95% CI) 615 321 38.8% 1.57[1.12.2.20] •TOlalevents 116
Heterogeneity: Chi' = 3.83,df=4 (P=0.43): 1'=0%
TestforoveralleffecI:Z=2.59(P=0.009)
1.13.5 Etanercepl
Sllbtotal (95% CI)
Tolalevents
Helerogeneily:Notapplicable
Test for overall effecl: Not applicable
1.13.60nercepl
Sllblotal (95% CI)
Total events
Helerogeneity:Nolapplicable
Test for overall effecl: Not applicable
Total (95%CI)
Total events 276 103
Heterogeneily'Ch,'= 1080.df= 10(P = 0.37): 1'=7%
TeslforoveralleffecI:Z=3.73(P=0.0002)
TestforsullQrollPd,fferences:Chi'=0.09,df=1(P=076).F=O%
1.50[1.21,1.86]
0.01 01 1 10 100
Favoursexpenmental Favours control
Figure 10. Infusion Reaction
TNF-alphaanta90nist Placebo Risk Ratio
Stud orSub rou Events Total Events Total Wei hI M-H,Fixed,95%CI
1.14.1Infliximab
Subtolal(95%CI)
Total evenIs
Helerogeneily:Notapplicable
Teslforoveralleffecl:Nolapplicable
Risk Ratio
M-H,Fixed,95%CI
Colombel2007 26 517 1 261 1.1% 13.13[1.79.96.19)
Hanauer 2006 66 225 12 74 14.7% 1.81 [1.04.3.15J
Sandborn2007a 17 159 17 166 13.5% 1.04[055. 197J
Sandborn2007b 29 258 2 18 3.0% 1.01 [0.26.3.91J
•Subtotal (95% CI) 1159 519 32.3% 1.79[1.22.2.63]Tolalevenls 138
Heterogeneily·Chi';7.30.df;3(P;0.06):I';59%
Testforoveralleffect:Z;2.98(P=0.003)
Sandborn2007c 9 331 47 329 38.3% 019[009,0381
Schreiber 2005 11 219 2 73 2.4% 183[0.42.8.081
Schreiber 2007 16 216 31 212 25.4% 0.51 [0.29.0.90J
•Subtotal (95% CI) 766 614 66.2% 0.37[0.25.0.56]Tolalevenls 36
Helerogeneity:Chi'=9.11.df=2(P=0.01):I'=78%
Teslforoveralieffect:Z=4.78(P<0.00001)
1.14.4CDP571
Subtolal (95% CI)
Total evenIs
Helerogeneily:Nolapplicable
Teslforoveralleffecl:Nolapplicable
1.14.60nercepl
Rulgeerls2006 170 0 37 0.7% 10.00[062. 16124J
Sublolal (95% CI) 170 37 0.7% 10.00[0.62, 161.24J
Total events
Helerogeneily:Nolapplicable
TeslforoveralieffecI:Z;1.62(P=010)
1.14.5Elanercept
Sandborn2001b 23 1 20 0.9% 2611029,23.13J
Subtotal (95% CI) 23 20 0.9% 2.61 [0.29. 23.13J
Total events
Helerogeneily:Nolapplicable
TeslforoveralleffecI:Z=0.86(p=0.39)
Tolal (95% CI)
Tolalevents 199 113
Heterogeneily:Chi'=41.00.df=8(P<0.00001):I'=80%
Teslforoveralleffecl:Z=0.69(P=0.49)
TestforsubQroupdifferences:Chi'=34.44.df=3(P<000001).I'=91.3%
Figure 11. Injection Site Reaction
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Figure 12. Funnel Plot of Serious Adverse Events
Table 1. Temporal Association of Adverse Events
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Results of Post Marketting Data
Meta-analysis (events/1000 patients)
(events/1000 Excluding Including17yr Including 5 yr
patients) Treat data TREAT data TREAT data
Death 2.0 66 7.7 17.2
Malignancy 4.0 13.5 13.5 18.0
Serious 24 41.0 33.5 72.1
Infections
Tuberculosis 13 1.0 11
Table 1. Temporal Comparison of Adverse Events
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Appendix A: Data Extraction
Data Extraction Tool
Risk of Bias Tool
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Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of ISD
Title
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Randomized Yes/No
Placebo Controlled Yes/No
Blinding Yes/No
Allocation concealment Yes/No
Treatment
Adverse events
Serious Adverse Events
Adverse events leading
to discontinuation
Death
Malignancy
Serious Infections
Pneumonia
Infusion Reactions
Injection site reactions
Other/Notes
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Appendix B: Data Extraction - Included Studies
A1. Adalimumab
A2. COP 571
A3. Certolizumab
A4. Etanercept
A5. Infliximab
AG. Onercept
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A1. Adalimumab
Data Extraction Form The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the
CLASSIC-I Trial. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Gastroenterology
2006;130323-33
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Weeks 0 and 2 with 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg or
placebo
• men and women;
• 18-75 years of age;
• Crohn's disease for at least 4 months;
• COAl score of 220-450 points;
• radiologic or endoscopic studies were required to confirm thed iagnosis
ofCrohn'sdisease;
• concurrent therapies for Crohn's disease, including5-aminosalicylates,
prednisone ($20 mg/day), budesonide($9mg/day),azathioprine,6-
mercaptopurine, methotrexate,andantibiotics,werepermittedatstable
dosages;
• femalepatientswithchildbearingpotentialwererequiredtousea highly
effective form of birth control;
• all patients were required to have adequate cardiac, renal,andhepatic
function
• history of malignancy;
• history of active tuberculosis, listeriosis, orHIV;
• ulcerative colitis;
• symptomatic obstructive strictures;
• underwent surgical bowel resection within 6 months;
• an ostomy;
• underwent extensive bowel resection (>100 cm) orhad short bowel
syndrome;
• total parenteral nutrition;
• received investigational chemical agents within 30 days;
• received investigational biologic therapy within 4 months;
• received antibiotic treatment within 3 weeks for infections not related to
Crohn'sdisease;
• pregnant;
• breast-feeding;
• clinically significant drug or alcohol abuse within 1 year;
• poorly controlled medical conditions;
• previously received infliximaboranyotheranti-TNFtherapy;
• received enema therapy within 2 weeks;
• received cyclosporineortacrolimuswithin 8 weeks;
• positive Clostridiumdiffici/estool assay;
• clinically significant deviations in prespecified laboratory parameters
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Duration of Treatment 4 weeks
Randomized Yes
Placebo Controlled Yes
Blinding Yes
Allocation concealment Yes
Adverse Events
Variable Plb ADA 40/20 ADA 80/40 ADA 160/80
(n = 74) (n=74) (n=75) (n=76)
Adverseevents,#(%) 55(74) 50(68) 51(68) 57(75)
Adverse events leading
to discontinuation 2(3) 1(1) 1(1) 0(0)
Adverse events
Abdominal tenderness 1(1) 1(1) 0(0) 4(5)
Crohn's disease aggravated 4(5) 2(3) 3(4) 2(3)
Crohn'sdisease 2(3) 4(5) 2(3) 3(4)
Nausea 1(1) 5(7) 4(5) 6(8)
Flatulence 3(4) 2(3) 2(3) 4(5)
Nasopharyngitis 1(1) 2(3) 4(5) 4(5)
Pharyngitis 2(3) 1(1) 1(1) 5(7)
Headache 4(5) 3(4) 4(5) 7(9)
Infections 12(16) 8(10) 13(17) 16(21)
Pneumonia 1(1) 0 0 2(3)
Serious adverse events 3(4) 0(0) 1(1) 3(4)
Serious infections 0(0) 0(0) 0(0) 2(3)
Perianal abscess 0(0) 0(0) 0(0) 1(1)
Pneumonia (SAE) 0(0) 0(0) 0(0) 1(1)
Lymphoma 0(0) 0(0) 0(0) 0(0)
TB 0(0) 0(0) 0(0) 0(0)
Injection site reactions 12(16) 19(26) 18(24) 29(38)
Injection site burning 6(8) 9(12) 8(11) 11(15)
Injection site pain 6(8) 6(8) 4(5) 6(8)
Injection site rx nonspecific 0(0) 3(4) 5(7) 6(8)
Injection site erythema 0(0) 1(1) 0(0) 3(4)
Injection site bruising 0(0) 0(0) 1(1) 2(3)
injection site pruritus 0(0) 0(0) 0(0) 2(3)
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Colombel 2007
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease
The CHARM trial. Colombel JF, Sandborn WJ, Rutgeerts P, et aI., Gastroenterolgy 2007;13252-
65
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Adalimumab
• adalimumab 80 mg (week 0) followed by 40 mg (week 2);
• at week 4, patients were stratified by response (decrease in Crohn's
Disease Activity Index >70 points from baseline) and randomizedto
double-blind treatment with placebo, adalimumab 40 mg every other
week (eow), or adalimumab 40 mg weekly through week 56
• men and women 18-75 years;
• known CD of at least 4 months'duration (radiologic/endoscopic
confirmation required);
• Crohn's Disease Activity Index (COAl) score of 220-450 points
• Concurrenttherapies:stabledosages(foratleast4weeksbefore
screening)ofazathioprine,6-mercaptopurine, methotrexate,5-
aminosalicylates, sulfasalazine, oral mesalamine, and CD-related
antibiotics;
• stable dosages (for at least 2 weeks before screening) ofprednisone(30
mg/day or equivalent) or budesonide (9 mg/day) (patients could not be
on both prednisone and budesonide);
• patients who had received infliximaborany TNF antagonist other than
adalimumabmorethan 12 weeks before screening could be enrolled
provided that they did not exhibit initial nonresponse to the agent(ie,no
clinical response to first injection as judged by the investigator);
• female patients of childbearing potential were required to use an
effective form of birth control
• ulcerative colitis;
• symptomatic obstructive disease;
• bowel resection within the past 6 months;
• an ostomy;
• extensivesmallbowelresection(asdeterminedbytheinvestigator);
• short bowel syndrome;
• currentiyreceiving total parenteral nutrition;
• a history of cancer;
• a history of Listeria or HI V;
• central nervous system demyelinating disease;
• untreated tuberculosis;
• received investigational chemical agents within 30 days;
• investigational biologic therapy within 3 months before screening;
• received antibiotic treatment for non-CO-related infections within 3
weeks before screening;
• pregnant or breast-feeding;
• significant drug or alcohol abuse within the past year;
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Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
• poorly controlled medical conditions;
• received treatment with adalimumab or participated in an adalimumab
clinical study;
• had received enema therapy within 2 weeks before screening;
• hadreceivedcyclosporine, mycophenolatemofetil,ortacrolimuswithin8
weeks of screening;
• had a positive Clostridiumdifficile stool assay;
• clinically significant deviations in prespecified laboratory parameters
56 weeks
July 2003 to September 2005
Yes
Yes
Yes
Blinded
Induction
Adverse events
Adverse events leading to
discontinuation of study drug
(Flare of CD)
Adverse events
CD flare
Arthralgia
Nasopharyngitis
Headache
Nausea
Fatigue
Abdominal pain
Pyrexia
Upper respiratory tract infection
Injection site reaction
Urinary tract infection
Influenza
Diarrhea
Pharyngolaryngeal pain
Serious adverse events
Infectious adverse events
Serious infectious adverse events
Selected injection site reactions
Bruising
Erythema
Hemorrhage
Irritation
Pain
Pruritus
Reaction
507(594)
54(6.3)
51(6.0)
45(53)
45(5.3)
130(15.2)
10(1.2)
1(0.1)
7(08)
4(0.5)
39(4.6)
41(4.8)
2(0.2)
17(2.0)
ADA 40 q2wk ADA 40 qwk
221(847) 231(88.8) 220(85.6)
35(134) 18(6.9) 12(4.7)
(7.7) (1.9) (12)
84(322) 51(196) 48(18.7)
23(8.8) 27(104) 34(13.2)
18(6.9) 29(112) 31(12.1)
15(5.7) 25(96) 30(11.7)
16(6.1) 19(73) 22(8.6)
6(2.3) 11(42) 20(7.8)
17(6.5) 20(7.7) 19(74)
14(54) 14(54) 17(6.6)
16(6.1) 12(4.6) 16(62)
1 (04) 11(4.2) 15(5.8)
4(1.5) 11(42) 15(58)
13(5.0) 14(54) 13(5.1)
15(5.7) 10(3.8) 12(4.7)
14(54) 11(42) 7(27)
40(153) 24(9.2) 21(8.2)
96(36.8) 120(462) 114(444)
9(34) 7(2.7) 7(27)
2(0.8) 6(2.3) 2(08)
0 7(27) 3(12)
2(0.8) 5(1.9) 0
2(0.8) 10(38) 7(2.7)
2(08) 5(1.9) 4(16)
0 3(1.2) 2(0.8)
1 (04) 11(4.2) 15(58)
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Adverse Events (cont.)
Induction Placebo ADA 40 q2wk ADA40qwk
Infections and infestations 10(1.2) 9(34) 7(2.7) 7(27)
Abscess 7(0.8) 5(1.9) 3(12) 5(1.9)
Tuberculosis 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Other opportunistic infections 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Woundinfection,sepsis,postopinf 3(04) 0(0.0) 0(0.0) 0(0.0)
Pneumonia 0(0.0) 0(0.0) 0(0.0) 1 (04)
Cancer (Breast) 0(0.0) 1 (04) 0(0.0) 0(0.0)
Multiple sclerosis 1(0.1) 0(0.0) 0(0.0) 0(0.0)
Serum sickness 1(0.1) 0(0.0) 0(0.0) 0(0.0)
Death (PE) 1(01) 0(0.0) 0(0.0) 0(0.0)
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Sandborn 2007A
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of ISO
Title: Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crahn disease
previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12)829-38
Treatment Studied
Inclusion Criteria
Exclusion Criteria
Adalimumab
160mgfoliowed by80mg in 2 weeks
• men and women 18 to 75yrs;
• Crahn disease for at least 4 months;
• moderately to severely active;
• COAl scoreof220-450 points;
• radiologic or endoscopic evidence to confirm the presence of CD;
• intolerantofinfliximabormusthavepreviouslyrespondedtoinfliximab
and then lost response;
• concurrent therapies, including stable dosages of5-aminosalicylates,
prednisone«=40mg/d),budesonide«=9mg/d),azathioprine,6-
mercaptopurine, methotrexate,andantibiotics,werepermitted
• primary nonresponseto infliximab;
• received infliximab or another TNF antagonist within the past 8 weeks;
• previously received adalimumab;
• participated in an adalimumabclinicaltrial;
• patients who changed dosages or discontinued azathioprine, 6-
mercaptopurine, or methotrexate treatment within 12 weeks of screening;
• patientswhochangeddosagesordiscontinued5-aminosalicylates,
mesalamine, or sulfasalazine treatment within 4 weeks of screening;
• prednisone;
• shortbowelsyndrame;
• symptomatic stricture;
• bowel resection within the past 6 months;
• ostomyorileoanalpouch;
• total parenteral nutrition;
• ptswhohadreceivedantibiotictreatmentforinfectionsnotrelatedto
Crohndiseasewithin3wks;
• untreated tuberculosis;
• demyelinating disorders;
• pregnant;
• breast-feeding;
• significant drug or alcohol abuse;
• abnormal results on electracardiography; or elevated concentrationsof
aspartate or alanine aminotransferase, total bilirubin orserumcreatinine
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Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding'
Allocation concealment
Variable
Adverse Events
Abdominal pain
Arthralgia
Headache
Injection-site irritation
Fatigue
Crohndisease
Injection-site reactions
Injection-site-related events
Bruising
Erythema
Hemorrhage
Irritation
Pain
Pruritus
Injection-site reaction
Adverse events
causing discontinuation
Serious adverse events
Infections
Serious infections
Abdominal abscess
Pelvic abscess
Perianal abscess
Staphylococcal sepsis
4-week
November 2004 to December 2005
Yes
Yes
Yes
Yes
Placebo Group Adalimumab Group
(n=166) (n=159)
121(73) 91(57)
12(7) 9(6)
3(2) 9(6)
12(7) 8(5)
7(4) 8(5)
9(5) 7(4)
15(9) 2(1)
17(10) 17(11)
1(0.6) 3(2)
0(0) 1(0.6)
0(0) 1(06)
7(4) 8(5)
4(2) 1(06)
0(0) 1(06)
6(4) 5(3)
4(2) 2(1)
8(5) 2(1)
3-abscess 2-dehydration
1-sepsis
2-CD
2-abdpain
39(24) 26(16)
4(2) 0(0)
1(0.6) 0(0)
1(06) 0(0)
1(06) 0(0)
1(06) 0(0)
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Sandborn 20078
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Gut. 2007;56(9):1232-9
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Adalimumab
open-labeladalimumab40mgatweeksOand2;
55 patients in remissionatbothweeksOand4were re-randomised to
adalimumab 40 mg every other week, 40 mg weekly, or placebo for 56
weeks
PatientsnotinremissionatbothweeksOand4wereenroliedinan
open-label arm and received adalimumab 40 mg every other week
• men and women;
• 18-75 years of age;
• crohn's disease for at least 4 months;
• COAl score of 220-450 points, inclusive;
• radiologic or endoscopic studies were required to confirm thediagnosis
ofCrohn'sdisease;
• concurrent therapies for Crohn's disease, including5-aminosalicylates,
prednisone (~20 mg/day), budesonide (~9 mg/day), azathioprine, 6-MP,
methotrexate, and antibiotics, were permitted at stable dosages;
• female patients with childbearing potential were required to usea highly
effective form of birth control;
• adequatecardiac,renal,andhepaticfunction
• history of malignancy;
• history of active tuberculosis, listeriosis, orHIV;
• ulcerative colitis;
• symptomatic obstructive strictures;
• underwent surgical bowel resection within 6 months;
• an ostomy;
• underwent extensive bowel resection (>100cm) or had short bowel
syndrome;
• total parenteral nutrition;
• received investigational chemical agents within 30 days;
• received investigational biologic therapy within 4 months;
• received antibiotic treatment within 3 weeks for infections notrelatedto
Crohn'sdisease;
• pregnant or breast-feeding;
• clinically significant drug or alcohol abuse within 1 year;
• poorly controlled medical conditions;
• previously received infliximaborany otheranti-TNF therapy;
• received enema therapy within 2 weeks;
• received cyclosporine ortacrolimuswithin 8 weeks;
• positive Clostridiumdifficilestoolassay;
• clinically significant deviations in prespecified laboratory parameters
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Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Patients
56 weeks
28 August 2002 and 12 January 2005
Yes
Yes
Yes
Yes
276 patients from CLASSIC I enrolled in CLASSIC II
Variable Randomised cohort Patients who received open-label treatment
or stopped atwk4
Adalimumab Adalimumab Adalimumab
40 mg Eow 40 mg weekly 40 mg EOW
(n=18) (n=19) (n=18) (n=221) (n = 276)
Adverse events 18(100) 15(79) 14(78) 207(94) 254(92)
Adverse events
leading to withdrawal 2(11) 1(5) 1(6) 39(18) 43(16)
Nasopharyngitis 7(39) 5(26) 2(11) 37(17) 51(19)
CD 5(28) 4(21) 2(11) 48(22) 59(21)
Sinusitis 1(6) 4(21) 1(6) 20(9) 26(9)
Injection-site RXN 2(12) 1(5) 0(0) 26(12) 29(12)
Rx-emergentinfectious
adverse events 15(83) 14(74) 6(33) 127(58) 162(59)
Malignancies 1(5) 0(0) 0(0) 0(0) 1(0.4)
Serious adverse
events 2(11) 1(5) 0(0) 37(17) 40(15)
Serious infections 0(0) 0(0) 0(0) 9(4) 0(0)
No demyelination
NoCHF
No Lupus
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A2. COP 571
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of ISO
Title: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's
disease. Stack WA, Mann SO, Roy AJ et aL Lancet. 1997;349:521-4
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
CDP571
CDP5715mg/kgx 1 dose
• aged 18-80 years;
• mild to moderately active Crohn'sdisease;
• Crohn's disease activity index between 150-400;
• a firm diagnosisofCrohn's disease previously made on acombinationof
radiological and histological criteria was required
• treatment with metronidazole, sodium cromoglycate, orcyclosporin
within the previous 3 months;
• positive stool culture for enteric pathogens;
• perforation or significant obstructive symptoms;
• history of asthma;
• pregnancy
Duration of Treatment 8 weeks
Randomized Yes
Placebo Controlled Yes
Blinding Yes
Allocation concealment ?
5/21 patientsreceivingCDP571 reported mild adverse reactions on the day of infusion
- Dizziness
- abdominal pain
- increased flatus
4/10 placebo recipients experienced similar symptoms
1.8 adverse drug reactions per patient for those receiving placebo
2.05 adverse drug reactions per patient for those receiving CDP571
Of these 0.01 per patient (placebo) and 0.14 per patient (CDP571) were probably related to treatment
In 7 patients, there was a small but significant and sustained rise in antibodies directed against CDP571
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Sandborn 2001A
Data Extraction Form The safety of TNF-alpha inhibitors used for the treatment of IBD
Title An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized
double-blind placebo-controlled trial. Sandborn WJ, Feagan BG, Hanauer SB, et al
Gastroenterology. 2001; 1201330-8
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
CDP571
10mg/kgor20mg/kgq80r12wk
• at least 18 years;
• moderate to severe Crohn's disease COAl 220-450;
• Crohn'sdisease based on radiological, endoscopic, or histological
evidence
• an ileostomy or colostomy
• serious intercurrent infection
• other clinically important active diseases (such a renal orhepatic
disease)
• those with bowel perforation, fixed stenosis at endoscopy or by
radiographic study within 6 months
• obstructive symptoms within 3 months (unless imaging studies showed
the absence of significant mechanical obstruction)
• small bowel resection >100 cm;
• more than the right colon resected;
• history of cancer other than cervical dysplasia or basal cell carci noma
within 5 years, dysplasia of the colon within 5 years
• clinically significant hematologic or biochemical values
• pregnant or breast-feeding women
• multiple drug allergies
• positive stool culture for enteric pathogens
• recent drug or alcohol abuse
• known hepatitisorhuman immunodeficiency virus
24 weeks
June 1998 and June 1999
Yes
Yes
Yes
Yes
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Variable No of patients (%)
Placebo CDP571
(n=58) (n=111)
No. of adverse events
Ptswithadverseevents
Ptswith serious adverse events
Ptswith severe adverse events
Most frequent adverse events (#events)
Abdominal pain
Asthenia
Fever
Flu syndrome
Headache
Infection
Body pain
Ileitis
Liver function test abnormality
Nausea
Vomiting
Depression
Dizziness
Insomnia
Pruritus
Rash
133
40(69%)
10(17%)
12(21%)
11 (19%)
2(3%)
2(3%)
4(7%)
6(10%)
6(10%)
6(10%)
7(12%)
1(2%)
9(16%)
5(9%)
1 (2%)
5(9%)
0(0%)
0(0%)
0(0%)
367
96(87%)
21 (19%)
26(23%)
12(11%)
7(6%)
7(6%)
10(9%)
20(18%)
16(14%)
9(8%)
12(11%)
6(5%)
16(14%)
7(6%)
6(5%)
10(9%)
7(6%)
6(5%)
6(5%)
Adverse events potentially associated with anti-TNF antibody therapy (no. of patients with events)
Infusion reaction 4(7%) 13(12%)
Abscess 2(3%) 5(5%)
Infection 6(10%) 16(14%)
Anti-double-stranded DNA present 0 (0%) 2 (2%)
Antinuclear antibody present 2(3%) 4(4%)
Anticardiolipin antibody present 2(3%) 3(3%)
Lupus syndrome 0(0%) 0(0%)
Lymphoma 0(0%) 0(0%)
Anti-idiotype antibody to CDP571 0 (0%) 8 (7%)
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Sandborn 2004
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to
severeCrohn'sdisease:arandomised,doubleblind, placebo controlled trial. SandbornWJ,
Feagan BG, Radford-Smith G, et al. Gut 2004 Oct;53(10):1485-93
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
CDP571
10mg/kgq8wk
• at least 18 years;
• moderate to severe Crahn's disease COAl 220-450;
• Crohn's disease based on radiological, endoscopic, or histological
evidence
• infectionofafistula;
• abscess;
• ulcerative colitis;
• bowel perforation;
• evidence of non-inflammatory obstruction within the six monthspriorto
study entry (fixed stenosis at endoscopy or radiography);
• obstructive symptoms due to significant mechanical obstruction within
the three months prior to study entry;
• small bowel resection >100cm;
• more than the right colon resected;
• a functional colostomy;
• an ileostomy;
• current infection with enteric pathogens;
• serious intercurrent infection;
• other clinically important active disease (such as renal orhepatic
disease) within the3 months prior to entry;
• currentorpreviousmalignancy(otherthancarcinomaofthecervixor
basal cell carcinoma successfully treated 5 years prior to study entry);
• current or previous bowel dysplasia within the five years prior to study
screening;
• clinically important allergies or multiple drug allergies;
• drug or alcohol abuse;
• significant abnormal haematology or biochemical values at studyentry;
• historyoforconcurrenttuberculosis,hepatitis,orhuman
immunodeficiency virus;
• pregnant and lactating women were ineligible
24 weeks
18 January 2001 and 15 May 2002
Yes
Yes
Yes
Yes
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Adverse Events
No of patients (%)
CDP571 Placebo
(n=133) (n =263)
Adverse Events 96(72.2) 200(760)
Serious Adverse Events 18(135) 27(10.3)
Withdrawal due to Adverse Events 26(19.5) 37(14.1)
Deaths 0(0) 0(0)
Patients with severeAEs 22(165) 46(17.5)
Patients with probably drug related AEs 3(2.3) 17(6.5)
Patients with definitely drug related AEs 1(08) 8(3.0)
Infections and infestations 39(29.3) 77 (29.3)
Headache 20(150) 32(12.2)
Crohn's disease aggravated 14(105) 22(84)
Nausea 8(60) 20(76)
Nasopharyngitis 7(5.3) 19(7.2)
Abdominal pain 6(4.5) 17(65)
Arthralgia 8(60) 13(49)
Vomiting 10(7.5) 10(38)
Pyrexia 7(5.3) 10(3.8)
Cough 8(6.0) 7(2.7)
Rectal Cancer 0 1(038)
Cervical Cancer 1(0.75) 0
Patients with AEs occurring within
2 hrs of the start of the infusion
Any 14(10.5) 54(20.5)
Hypersensitivity 0(0) 7(2.7)
Dizziness 1(0.8) 5(19)
Dermatitis 0(0) 4(1.5)
Headache 4(3.0) 2(0.8)
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Data Extraction Form The safety of TNF-alpha inhibitors used for the treatment of IBD
Title: A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal
antibody to tumour necrosis factor-alpha, inpatientswithcorticosteroid-dependentCrohn's
disease. Feagan BG, Sandborn WJ, Baker JP, et al. Aliment Pharmacol Ther. 2005;21373-384
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
CDP571
CDP571 1Omg/kg q8wk
• at least 18 years;
• Crohn's Disease Activity Index (CDAI) score less than or equal to 150
points (indicating remission);
• corticosteroid therapy with prednisolone or prednisone 15-40mg/dayor
budesonide9 mg/day to control symptoms for at least 8 weeks;
• at least one unsuccessful attempt to discontinue prednisolone,
prednisone or budesonide therapy (defined as worsening symptoms
within 30 days) within 8 weeks of study entry;
• a stable corticosteroid dose (except during attemptedwithdrawaI)forat
least 2 weeks prior to screening
• useofbroad-spectrumantibiotics,mycophenolatemofetil,cyclosporinor
sodium cromoglycate within 1 month of screening;
• ulcerative colitis;
• extensive bowel resection (>100cm of the small intestine);
• extended right hemicolectomy;
• a stoma;
• obstructive symptoms;
• radiographic evidence of fixed, noninflammatory bowel obstruction within
the6monthspriortostudyentry;
• history of bowel perforation;
• critical illness;
• active infections (including enteric pathogens);
• multiple drug allergies;
• othersignificantmedicalconditions(includingmalignancy,except
carcinoma of the cervix or basal cell carcinoma of the skin);
• current or previous bowel dysplasia within 5 years;
• significant abnormal haematology or biochemical values at studyentry;
• history of hepatitis or human immunodeficiency virus;
• pregnancy or lactation;
• previous treatment with infliximab or other anti-TNF-a therapy (except
CDP571);
• experimental immunomodulatory antibodies, cytokines or drugs (within
the preceding 3 months);
• participation in any other clinical trial (within the preceding 1 month);
• intravenous corticosteroids or corticotrophin (within 1 month);
• corticosteroid treatment for other diseases (except topical hydrocortisone
or inhaled corticosteroids for pulmonary disease) within the preceding6
months; discontinued antimetabolite therapy within the preceding month
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Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealed
16 weeks
4June 1998 and 10 November 1999
Yes
Yes
Yes
Yes
No. of patients (%)
Placebo
(n=32)
CDP57110mg/kg
(n=39)
Number of adverse events
Patients with adverse events
Patients with serious adverse events
Patients withdrawn due to adverse events
Deaths
Patients with severe adverse events
Patients with possibly, probably or
definitely drug-related adverse events
Flu syndrome
Asthenia
Abdominal pain
Headache
Vasodilation
Dizziness
Antinuclear antibody
Diarrhoea
Nausea
Dry skin
Abscess
Infection
Pain
112
25(78.1)
3(94)
1(31)
o
7(21.9)
17(531%)
5(15.6)
5(15.6)
4(12.5)
4(125)
1(31)
3(94)
3(94)
1(31)
o
o
2(63)
1(31)
o
177
35(897)
4(10.3)
7(179)
o
8(20.5)
24(615%)
2(5.1)
o
5(12.8)
5(128)
4(10.3)
4(103)
3(77)
3(7.7)
3(7.7)
3(7.7)
o
2(51)
2(5.1)
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FEAGAN 2006
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title: CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-
dependent Crohn's disease: A randomized, double-blind, placebo-controlled trial. Feagan BG,
Sandborn WJ, Lichtenstein G, et al. Aliment Pharmacol Ther. 2006;3: 617-628
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
CDP571
CDP571 10mg/kg q8wk
• at least 18 years;
• steroid-dependentCrohn's disease defined as: (i) the
requirement for steroid treatment with prednisolone or
prednisone (15-40 mg/day),orbudesonide(9 mg/day)
for at least 8 weeks (although the dose could have
been temporarily reduced during an attempt at steroid
withdrawal),withastabledoseforatleast2weeks
prior to study entry; (ii) an unsuccessful attempt to
decrease or discontinue steroid treatment, owing to
disease flare within 30 days of the attempt, on at least
one occasion in the 8 weeks prior to study entry;
• all patients had a baseline score of 150 points on the
Crohn's Disease Activity Index (CDAI);
• the diagnosis ofCrohn's disease was made using radiological,
• endoscopical,orhistologicalevidence
• infection ofa fistula (abscess);
• ulcerative colitis;
• bowel perforation;
• evidenceofa non-inflammatory obstruction (within 6 months);
• obstructive symptoms owing to significant mechanical obstruction (within
3 months);
• small bowel resection >100 cm and/or more than the right colon resected
• colostomy;
• ileostomy;
• infectious enteritis;
• other serious infection;
• clinically important chronic disease in the3 months before study entry;
• history of blood dyscrasia (pancytopenia or aplastic anaemia) ;
• demyelinating disease;
• currentorpreviousmalignancyotherthansuccessfullytreated
carcinomaofthecervixorbasalcellcarcinoma(> 5 years priortoentry);
• current or previous bowel dysplasia (5 years before screening) ;
• clinically important allergies;
• multiple drug allergies;
• drug or alcohol abuse;
• significant abnormal haematology or biochemical values;
• concurrent tuberculosis, hepatitis, orHIV;
• pregnant and lactating women
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Duration of Treatment
Duration of Study
Randomized:
Placebo Controlled
Blinding
Allocation concealment
32 weeks
30 Nov 2000 and 13 May 2002
Yes
Yes
Yes
Yes
No.ofpatients(%)
Placebo (n =88) CDP571 (n =181)
AEs possibly or probably related to treatment
Crohn's disease aggravated 12 (13.6)
Headache 11 (125)
Nausea 4 (4.5)
Arthralgia 3(34)
Abdominal pain 3(34)
Dermatitis 6(68)
Sore throat 2 (2.3)
Pyrexia 3(34)
Viral infection 6(6.8)
Upper respiratory tract infection 6 (6.8)
Nasopharyngitis 6(6.8)
Back pain 6 (6.8)
Urinary tract infection 7(8.0)
Patients with adverse events
Patients with serious adverse events
Patients with severe adverse events
Patients with possibly, probably,
or definitely drug-related AEs
Patients with AEs leading to withdrawal
Deaths
Patients with AE occurring within 2h - Any
Hypersensitivity
Urinary tract infection
Headache
Chest tightness
Flushing
Hypertension
Nausea
Taste disturbance
Urticaria
Any infection
Urinary tract infection
Viral infection
Upper respiratory tract infection
Nasopharyngitis
Sinusitis
Influenza
Abdominal abscesses
Skin/subcutaneoustissueabscess
Scrotal infection
Escherichia coli sepsis
62(70.5)
6(6.8)
9(10.2)
37(42.0)
9(102)
0(0)
13(148)
o
2(23)
2(2.3)
o
o
o
o
o
o
32(364)
7(8.0)
6(6.8)
6(6.8)
6(68)
o
4(4.5)
o
o
o
o
128(707)
22(122)
32(17.7)
76(42)
23(127)
1(06)
34(188)
30(16.6)
16(8.8)
16(88)
14(7.7)
12(66)
11(61)
9(5.0)
8(44)
7(39)
6(33)
6(33)
5(28)
39(22.8)
7(39)
4(2.2)
2(1.1)
2(1.1)
2(11)
2(11)
2(1.1)
2(1.1)
2(1.1)
57(315)
5(28)
8(44)
7(39)
6(3.3)
7(3.9)
1(0.6)
2(1.2)
1(06)
1(0.6)
1(0.6)
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A3. Certolizumab
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour
necrosis factor antibody, in patientswithmoderate-to-severe Crohn'sdisease:an
exploratory study. Winter TA, Wright J, Ghosh S, et aL Aliment Pharmacol Ther
2004;20:1337-46
Treatment Studied Certolizumab (CDP870)
Dose CDP870 (1.25,5,10 or 20 mg/kg body weight diluted with normal saline to a
fixed volume (100 mL)
Inclusion Criteria
• at least 18 years;
• clinicaldiagnosisofmoderate-to-severeCD,confirmedbyradiological,
endoscopic or histological evidence;
• Crohn's Disease Activity Index (CDAI) score of 220-450 points;
• permitted to receive concomitant medication, provided the dose had been stable
prior to the start of the study;
• for the following durations: 8 weeks for azathioprine, methotrexate and
mercaptopurine (6-mercaptopurine);
• 4weeksforlong-termantibiotics,sulfasalazine(sulphasalazine), mesalazine,
0Isalazine,pentasaorsimilaranalogues;2weeksforcorticosteroidsandtopical
anorectaltreatments.Concomitantmedicationsalsohadtobestable during the
12-week study period
Exclusion Criteria
• fistula;
• abcess;
• ulcerative colitis;
• bowel perforation;
• obstruction or history of obstructive symptoms;
• extensive bowel resection (> 100 cm of small bowel and/or more than the right
side of the colon resected);
• a functional colostomy or ileostomy;
• a positive stool result for enteric pathogens;
• previous treatment or participation in a clinical trial with anti-TNF therapy within
12 weeks of screening;
• previous history of serious infection or tuberculosis;
• clinicallysignificantabnormalhaematologicalorbiochemistryvalues;
• any other medical conditions considered by the investigator to warrant exclusion
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Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Placebo
(0=24)
AnyAEs
2(83)
0(00)
AEsunrelatedto
treatment
Aggravated CD 1(4.2)
Drug Overdose 0
O(O}
Nasopharyngitis 1(4.2)
12 weeks
September 2001 and April 2002
Yes
Yes
Yes
Yes
CDP870 CDP870 CDP870 CDP870 CDP870
1,25 (mg/kg) 5(mg/kg) 10 (mg/kg) 20(mg/kg) All doses
(n=2) (0=26) (n=17) (0=23) (n=68)
11(64.7)
0(00) 1(38) 1(5.9) 7(103)
0(0.0) 1(38) 0(0.0) 1(43) 2(29)
1(50.0) 7(269) 6(353) 12(522) 26(38.2)
3(4.4)
2(29)
2(29)
4(59)
NoTB,death,lupus.Noinfusionreactions
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Schreiber 2005
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Tille CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of
certolizumab pegol (CDP870) for treatment of Crohn's disease. Schreiber S, Rutgeerts P,
Fedorak R,etal. Gastroenterology. 2005;129:807-18
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Certolizumab
100mg,200mg&400mg
• at least 18 years old;
• clinical diagnosis ofCrohn's disease;
• confirmed by radiologic, endoscopic, or histologic evidence;
• patients had moderate to severe disease with 220-450 points on the
COAl
• suspected or diagnosed abscess;
• a bowel perforation or evidence of noninflammatory obstruction during
the prior 6 months;
• extensive bowel resection;
• colostomy or ileostomy;
• positive stool culture for enteric pathogens;
• tuberculosis;
• treatment for Crohn's disease with sodium cromoglycate,
mycophenolate, orcyclosporin within 4 weeks;
• other anti-TNF therapy with a biologic agent within 12 weeks of
screening;
• patients were also excluded from the study if they had been treated
previously with any anti-TNF agent and either had experienced an
infusion reaction that was suspected or confirmed to beassociated with
an immune response;
• primarynonresponder;
• participation in another clinical trial with certolizumab;
• involved in any other clinical drug trial within the4 weeks before
screening
12 weeks
February 15, 2001, and March 12,2002
Yes
Yes
full blinding was not possible becausecertolizumaband placebo did not
have the same color or viscosity
?No
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Adverse Events
Placebo CTZ100mg CTZ200mg CTZ400mg
(n=73) (n= 74) (n=72) (n=73)
Nasopharyngitis 3(41) 9(122) 7(97) 4(5.5)
Influenza 3(41) 4(5.4) 3(42) 1(1.4)
Fungal infection 0 2(27) 1(1.4) 2(27)
Sinusitis NOS 3(4.1) 2(27) 2(28) 0
Gastroenteritis
Ecoli/Camp 0 1(1.4) 1(1.4) 1(1.4)
Bronchitis 2(2.7) 2(27) 1(1.4) 0
UTI 5(6.8) 1(1.4) 1(1.4) 0
Pharyngitis 0 0 0 2(2.7)
Herpes zoster 0 0 1(1.4) 1(1.4)
Herpes simplex 1(1.4) 1(1.4) 0 1(1.4)
URTI 1(1.4) 1(1.4) 0 1(1.4)
Vaginosis 1(1.4) 0 2(2.8) 0
Oral candidiasis 1(1.4) 0 1(1.4) 0
Abscess 0 2(27) 0 0
Tooth abscess 1(1.4) 2(27) 0 0
Injection Site RXN 2(2.7) 5(68) 4(56) 2(27)
Weeks 13-20
Nasopharyngitis 4(5.5) 4(5.4) 3(4.2) 3(4.1)
Sinusitis 0 1(1.4) 2(28) 0
Bronchitis 0 1(1.4) 1(1.4) 0
Gastrointestinal
infection NOS 1(1.4) 0 1(1.4)
Influenza 2(2.7) 1(1.4) 0
GI NOS 2(2.7) 0 0
Weeks 0-12
AnyAE 51(699) 57(77.0) 55(76.4) 48(658)
SeriousAE 6(82) 7(95) 10(139) 6(82)
AE leading to
withdrawal 7(9.6) 9(12.2) 7(97) 7(96)
Relationship to
study medication
Unrelated 42(57.5) 43(58.1) 44 (611) 37(507)
Possible 34(466) 35(47.3) 41(569) 27(370)
Probable 3(4.1) 4(5.4) 7(9.7) 3(4.1)
Definite 1(1.4) 2(27) 3(4.2) 0(0.0)
Weeks 13-20
AnyAE 37(50.7) 28(37.8) 31(43.1) 26(356)
SeriousAE 11(151) 1(1.4) 3(4.2) 4(5.5)
AE leading to
withdrawal
Relationship to study
Medication
Unrelated 34(466) 24(32.4) 25(34.7) 21(288)
Possible 7(9.6) 5(6.8) 9(12.5) 9(12.3)
Probable 0 0 0 0
Definite 0 0 0 0
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Other Side Effects (Text)
Headache
Aggravation CD
Nausea
Nasopharyngitis
Dizziness
Arthalgia
Abd Pain
Pharyngolaryngeal Pain
Pyrexia
Infection
Placebo
16.4%
137%
5.5%
4.1%
4.1%
2.7%
5.5%
5.5%
4.1%
17(23.3%)
eTZ
132%
11.9%
11.4%
9.1%
6.4%
5.9%
59%
5.0%
5.0%
58(26.5%)
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Schreiber 2007
Data Extraction Form The safety of TNF-alpha inhibitors used for the treatment of IBD
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease (Precise 2)
Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al. N Engl J Med 2007;357239-50
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Certolizumabpegolorplacebosubcutaneously
• 400mgatweeksO,2,and4andthenevery4weeks;
• at week 6 patients were stratified according to their baseline C-reactive
protein level and were randomly assigned to receive 400 mg of
certolizumabpegolorplaceboevery4weeksthroughweek24,with
follow-up through week 26
• active Crohn's disease for at least 3 months;
• CDAI: 220 to 450;
• patients could receive concomitant therapy with stable doses 0 f5-
aminosalicylates, prednisolone or its equivalent (30 mg perdayorless),
azathioprine,6-mercaptopurine,methotrexate,orantibiotics
• short-bowel syndrome;
• ostomy;
• obstructive symptoms with strictures;
• abscess;
• history ofTB (positive results on chest radiography orthe purified-
protein-derivative tuberculin skin test);
• demyelinating disease;
• cancer;
• any anti-TNFagentwithin the previous 3 months;
• severe hypersensitivity reaction to anotherTNF antagonist;
• a lack of response to the first dose of another TNF antagonist
24 weeks
February 2004 until May 2005
Yes
Yes
Yes
Yes
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Adverse Events
CTZ (Wk 0-6) CTZ Main (Wk 6-26) Placebo
(n=668) (n=212) (n=216)
Any 392(59) 143(67) 140(65)
Headache 84(13) 14(7) 15(7)
Nasopharyngitis 25(4) 8(4) 12(6)
Cough 5«1) 2«1) 12(6)
CD (exacerbation) 36(5) 25(12) 9(4)
Pain (injection site) 8(1) 11(5) 1«1)
Related to study drug
(as determined by PI) 161(24) 58(27) 49(23)
Any local rxtoinjection 13(2) 31(15) 6(3)
Serious adverse events 47(7) 14(7) 12(6)
Infection or infestation 12(2) 2«1) 6(3)
Abdominal abscess 4«1) 1«1) 0
Perianal abscess 4«1) 0 1«1)
Perineal abscess 0 0 2«1)
Bacteremia 0 1«1) 0
Otitis media 0 1«1) 0
Pneumonia 0 0 1«1)
Pyelonephritis 0 0 1«1)
Tuberculosis 0 0 1«1)
Viral gastroenteritis 1«1) 0 0
Infection 1«1) 0 0
Lobar pneumonia 1«1) 0 0
Pelvic inflammatory ds 1«1) 0 0
AnyGldisorder 29(4) 9(4) 4(2)
Obstructive events 7(1) 1«1) 0
Abdominal pain 1«1) 1«1) 2«1)
Exacerbation of CD 19(3) 5(2) 1«1)
Diarrhea 1«1) 0 1«1)
Other 1«1) 2(2) 0
Blood and lymphatic
-system disorder 1«1) 0 1«1)
Iron-deficiency anemia 0 0 1«1)
Anemia 1«1) 0 0
Immune-system disorders 1«1) 1«1) 0
Benign, malignant, or
unspecified neoplasm
(including cysts and polyps) 1«1) 0 0
Leading to withdrawal 51(8) 28(13) 18(8)
Leading to death 1«1) 0 0
• 1 Death in CTZ group was an accidental fentanyl overdose
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Sandborn 2007C
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Certolizumab Pegol for the Treatment of Crohn's Disease (Precise 1) Sandborn
WJ, Feagan BG, Stoinov S, et aL N Eng! J Med 2007;357:228-238
Treatment Studied Certolizumab pegol or placebo subcutaneously
Dose 400mgatweeksO,2,and4andthenevery4weeks
Inclusion Criteria
• active Crohn's disease for at least 3 months;
• COAl: 220 to 450;
• Patients could receive concomitant therapy with stable doses 0 f5-
aminosalicylates,predniso!oneoritsequivalent(30mgperdayorless),
azathioprine,6-mercaptopurine,methotrexate,orantibiotics
Exclusion Criteria
• short-bowel syndrome;
• ostomy;
• obstructive symptoms with strictures;
• abscess;
• hxTB (positive results on chest radiography or the purified-protein-
derivative tuberculin skin test);
• demyelinating disease;
• cancer were not eligible;
• any anti-TNF agent within the previous 3 months;
• severe hypersensitivity reaction to anotherTNF antagonist;
• a lack of response to the first dose of another TNF antagonist
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
26-week
December 2003 and May 2005
Yes
Yes
Yes
Blinded
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Adverse Events
Placebo Group Certolizumab Group
(N = 329) (N= 331)
Any adverse event 260(79) 269(81)
Headache 54(16) 60(18)
Nasopharyngitis 27(8) 44(13)
Abdominal pain 37(11) 37(11)
Exacerbation of CD 37(11) 33(10)
Nausea 27(8) 26(8)
Urinary tract infection 17(5) 25(8)
Arthralgia 16(5) 22(7)
Pyrexia 22(7) 21(6)
Vomiting 11(3) 18(5)
Back pain 17(5) 9(3)
Injection-site pain 23(7) 4(1)
Event related to study drug 120(36) 108(33)
Any injection-site reaction 47(14) 9(3)
Serious adverse events 23(7) 34(10)
Infection 3«1) 7(2)
Abscess
Perianal 2«1) 4(1)
Muscle 0 1«1)
Limb 0 1«1)
Any 1«1) 0
Gastroenteritis 0 1«1)
Urinary tract infection 0 1«1)
Neoplasm
and polyps) 2«1) 2«1)
Metastatic lung cancer 0 1«1)
Rectal cancer 0 1«1)
Cervical carcinoma 0 1«1)
Hodgkin's disease 1«1) 0
Adverse events leading to
withdrawal from study 39(12) 36(11)
Adverse events leading todeath* 0 1«1)
* 1 Death in CTZ group was a 22 yo Myocardial Infarction/ Met Lung Cancer
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A4. Etanercept
Sandborn 2001 B
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled
Trial. Sandborn WJ, Hanauer SB, Katz S, et aL Gastroenterology 2001; 121:1088-1 094
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Etanercept
25mgorplacebotwiceweekly
• at least 12 years of age;
• moderatelytoseverelyactiveCrohn'sdisease;
• COAl: 220-450;
• CD confirmed by radiologic, endoscopic, or histologic criteria
• ileostomy;
• colostomy;
• immediateneedforsurgeryforactivegastrointestinalbleeding,
peritonitis,intestinalobstruction,orintra-abdominalorpancreatic
abscess requiring surgical drainage;
• those with local or systemic infection (including septic lesionsinthe
perianal region those with symptoms of bowel obstruction within the
preceding 6 months confirmed with objective radiographic orendoscopic
evidenceofastricturewithresultingobstruction(dilationofthebowel
proximal to the stricture on bariumoran inabiiity to traversethe stricture
atendoscopy),which had not been surgically corrected;
• a planned inpatient hospitalization during the study;
• other clinically important active diseases (such as renal orhepatic
disease);
• an active fistula to the vagina or bladder;
• a history of cancer within 5 years, dysplasia of the colon within 5 years,
or clinically significant hematological or biochemical valueswere also
ineligible;
• pregnant or breast-feeding women;
• history of drug or alcohol abuse within 6 months
8 weeks
September 1999 and May 2000
Yes
Yes
Yes
Yes
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Placebo Etanercept
(n=20) (n=23)
No. of adverse events
No. ofptswith adverse events
No. of pts with serious adverse events
No. of pts with severe adverse events
Most frequent AE (no. of events)
Headache
New injection site reactions
Asthenia
Abdominal pain
Mild anemia
Skin disorders
19
10(50%)
2(10%)
3(15%)
1 (5%)
1 (5%)
0(0%)
2(10%)
0(0%)
0(0%)
34
17(74%)
1(4%)
1(4%)
3(13%)
3(13%)
2(9%)
0(0%)
2(9%)
2(9%)
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AS. Infliximab
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title A Short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha
for crohn's disease. Targan SR, Hanauer SB, van Deventer SJ, et al. N Engl J Med
1997;337(15):1029-35
Treatment Studied a single dose of either placebo or 5 mg of cA2 per kilogram of body weight, 10
mg of cA2 per kilogram, or 20 mg of cA2 per kilogram IV
Inclusion Criteria
• Crohn's disease for six months;
• CDAI between 220 - 400;
• concomitant medications allowed: mesalamine for eight or more weeks,
with stable dose. A maximum of 40 mg of corticosteroids per day for
eight or more weeks, with the dose remaining stable during the two
weeks before screening; and mercaptopurine or azathioprine forsixor
more months, with the dose remaining stable during the eight weeks
before screening
Exclusion Criteria
• iftheyhadreceivedtreatmentwithcyclosporine, methotrexate,or
experimental agents within three months before screening;
• symptomatic stenosis or ileal strictures;
• proctocolectomyortotalcolectomy;
• stoma;
• a history of allergy to murine proteins;
• prior treatment with murine, chimeric, or humanized monoclonal
antibodies; or treatment with parenteral corticosteroids orcorticotropin
within four weeks before screening
Duration of Treatment
Duration of Study
Randomized'
Placebo Controlled
Blinding
Allocation concealment
2 hours
June21, 1995-March12, 1996
Yes
Yes
Yes
Yes
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Adverse Events
Placebo One Dose Two doses
ofcA2 ofcA2
(n=25) (n=102) (n=29)
Adverse effect - no. of patients (%)
Any adverse effect 15(60) 76(75) 23(79)
Headache 5(20) 19(19) 3(10)
Nausea 2(8) 11(11) 5(17)
Upper respiratory tract infection 3(12) 8(8) 4(14)
Fatigue 1(4) 6(6) 3(10)
Myalgia 1(4) 4(4) 3(10)
Rhinitis 1(4) 3(3) 3(10)
Pain 0 4(4) 3(10)
Pruritus 1(4) 1(1) 4(14)
Chest pain 1(4) 2(2) 3(10)
Vomiting 0 2(2) 3(10)
Dyspnea 0 1(1) 3(10)
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Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of ISO
Title
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Infliximabforthetreatmentoffistulasinpatient'swithCrohn'sdisease
Present DH, Rutgeerts P, Targan S, et al. N Engl J Med
1999;340(18)1398-405
Infliximab
5 mg/kg of infliximab or 10 mg/kg
• 18to65 years of age;
• single or multiple draining abdominal or perianal fistulasofa tleastthree
months duration;
• Crohn'sconfirmed by radiography, endoscopy, or pathological
examination;
• patients could receive concomitant therapy: acceptable regimens were
aminosalicylatesata dosage that had been stable for more than four
weeks before screening; oralcorticosteroidsatadosageof40mgor
lessperdaythathadbeenstableformorethanthreeweeks;
methotrexate given for at least three months at a dosage that had been
stable for more than four weeks; azathioprine or mercaptopurinegiven
for at least six months ata dosage that had been stable for more than
eight weeks; and antibiotics ata dosage that had been stable for more
than four weeks;
• if patients were not currently receiving treatment with anyofthese
medications, they had to have discontinued therapy at leastfourweeks
before enrollment
• cyclosporine
• treatment with investigational agents
• treatment with an antiTNF within three months before enrollment;
• complications of Crohn'sdisease, such as current strictures 0 r
abscesses;
• presenceofastomacreatedlessthansixmonthsbeforeenrollment;
• a history of allergy to murine proteins;
• previoustreatmentwithinfliximab
Doses given 0, 2,6weeks
May30throughOctober1,1996
Yes
Yes
Yes
Yes
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Adverse Events
Infliximab Infliximab Infliximab
5mg/kg 10mg/kg 50r10 mg/kg
(n=31) (n=31) (n=32) (n=63)
Headache 7(23) 5(16) 6(19) 11(17)
Abscess 1(3) 2(6) 5(16) 7(11)
URTI 2(6) 1(3) 5(16) 6(10)
Fatigue 2(6) 2(6) 4(12) 6(10)
SAE 0 1(3) 4(12) 5(8)
Discontinued (SE) 0 0 1(3) 0
Pneumonia 0 0 1(3) 0
Obstruction 0 0 1(3) 0
Arm Abscess 0 0 1(3) 0
Anal Abscess 0 0 1(3) 0
UrethralObs 0 1(3) 0 0
Infusion Reaction
(Within2hrs) 4(6)
DSDNA 8(13)
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Rutgeerts 1999
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain
remission in Crohn's disease. Rutgeerts P, D'Haens G, Targan S, et al. Gastroenterology
1999;117(4)761-9
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Infliximab
10mg/kginfliximabgivenevery8weeks
• Crohn's disease for six months;
• CDAI between 220 - 400;
• concomitant medications allowed: mesalamine for eight or more weeks,
with stable dose. A maximum of 40 mg of corticosteroids per day for
eight or more weeks, with the dose remaining stable during the two
weeks before screening; and mercaptopurineorazathioprineforsixor
more months, with the dose remaining stable during the eight weeks
before screening;
• in addition, patients who had notrespondedtoaminosalicylates, 6-
mercaptopurine,azathioprine, methotrexate,orcyclosporinewere
eligible for the study
• symptomatic stenosis or ileal strictures;
• proctocolectomyortotalcolectomy;
• stoma;
• a history of allergy to murine proteins;
• prior treatment with murine, chimeric, or humanized monoclonal
antibodies; or treatment with parenteral corticosteroids orcorticotropin
within four weeks before screening
36 weeks
?
Yes
Yes
Yes
?
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Adverse Events
Placebo Infliximab
Retreatment (10mg/kg)
(n=36) Retreatment
(n=37)
Adverse events (# patients) 35(97.2) 35(94.6)
Withdrawal because of AE 1(2.8) 6(16.7)
Adverseevents,n(%)
URTI 6(167) 9(24.3)
Headache 4(111) 6(16.2)
Abdominal pain 5(13.9) 5(135)
Nausea 3(8.3) 7(18.9)
Fever 5(139) 4(108)
Bronchitis 3(8.3) 6(162)
Pharyngitis 1(28) 7(189)
Lymphoma 1(2.8) 0
Antids DNA 2(1 Lupus) 0
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Hanauer 2002
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Hanauer SB,
Feagan BG, Lichtenstein GR, etal. Lancet. 2002;359:1541-9
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Infliximab
5mg/kg IV infusion ofinfliximab at week 0
After assessment of response at week 2, patients were randomly
assigned repeat infusions of placebo at weeks 2 and6 and then every8
weeksthereafteruntilweek46(groupl),repeatinfusionsof5mgIkg
infliximab at the same timepoints (group II), or 5 mg/kg infliximab at
weeks2and6followedby 10mg/kg (group III)
• men and women;
• 18-75 years of age;
• Crohn's disease for at least 3 months;
• COAl score of 220-400 points;
• concurrent therapies forCrohn's disease, including5-aminosalicylatesor
antibiotics (constant dose for 4 weeks before the screening vis it);
corticosteroids(prednisone,prednisolone,orbudesonide)atthe
equivalentof40mgperdayofprednisoneorless(stabledosefor3
weeks);azathioprineand6-mercaptopurine(stabledosefor8weeks);or
methotrexate (stable dose for 6 weeks).
• previous treatment with infliximab or any other agent targeted at TNF
46 weeks
Feb 26, 1999-March 15,2001
Yes
Yes
Yes
Yes
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Adverse Events
Group I Group" Group III Total
(n=188) (n=193) (n=192) (n=573)
Adverse events leading to 5(3) 29(15) 16(8) 50(9)
discontinuation of study agent
Serious adverse events
All events 55(29) 54(28) 43(22) 152(27)
Reasonably related 13(7) 15(8) 11(6) 39(7)
Infections
Infectionrequiringantimicrobialrx 70(37) 64(33) 52(27) 186(32)
Serious infection 8(4) 8(4) 6(3) 22(4)
Intestinal stenosis 6(3) 3(2) 5(3) 14(2)
Infusion reactions 17(9) 44(23) 36(19) 97(17)
Serum-sickness-likereactions 3(2) 5(3) 6(3) 14(2)
Death (sepsis from obstruction) 1«1)
Malignancy
ANA & Anti DNA 19(11) 123(34) 363(56)
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Data Extraction Form The safety of TNF-alpha inhibitors used for the treatment of IBD
Infliximabin moderately severe glucocorticoid resistantulcerativecolitis:Arandomised
controlled triaL Probert CS, Hearing SO, Schreiber S, et aL Gut. 2003;52(7)998-1002
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Infliximab
5mg/kgbodyweightorpiaceboatweekOandasecondidenticai
infusion at week 2
• age 18 years or older;
• establisheddiagnosisofUC;
• failed to respond to conventional treatment with glucocorticoids;
• not in need of urgent colectomy;
• patients had to have received conventional treatment with at Ieast30mg
prednisolone (or equivalent) for at least one week for relapse, but still
had clinical activity that qualified for inclusion in the study;
• ulcerative colitis symptom score (UCSS) of 6 or more;
• a sigmoidoscopy score of at least 2 on the Baron scale;
• biopsy taken showing histological changes of acute ulcerative colitis
• fulminant disease likely to require colectomy;
• pregnant or planning a pregnancy during or within six months ofthe trial;
• cyclosporine;
• any investigational drug within three months of enrolment;
• those who had commenced treatment (within the last three months) with
6-mercaptopurine or azathioprine were also excluded;
• stabledoseof6-mercaptopurineorazathioprineformorethanthree
months were not excluded;
• any patient with a gastrointestinal infection was excluded;
• known serious infections (such as hepatitis, pneumonia, pyelonephritis,
oranopportunisticinfection);
• in the previous three months;
• past or current colorectal dysplasia;
• malignancy;
• Crohn'sdisease;
• prior intestinal resection;
• appendicectomy;
• presence ofa stoma were also exclusion criteria
Duration of Treatment 6 weeks
Randomized Yes
Placebo Controlled Yes
Blinding Yes
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Placebo group Twoseriousadverseevents
One patient suffered septic complications
Disease exacerbation and spontaneous perforation
All other serious adverse events were rated as mild and were notsignificantly different in frequency
between infliximaband placebo treated patients
No significant infusion reactions were seen
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Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title: Infliximab Maintenance Therapy for Fistulizing Crahn's Disease. Sands BE, Anderson FH,
Bernstein CN et al. N Engl J Med. 2004;350:876-85
Treatment Studied Infliximab
Dose 5mg/kg(0,2,6thenq8wk)
Inclusion Criteria
• men and women;
• 18 years of age or older;
• Crohn'sdiseasewhohadhadsingleormultipledrainingfistulas;
• perianal fistulas and enteracutaneousfistulasforat leastthreemonths;
• women with rectovaginafistulaswere included if they had at leastone
otherenterocutaneous draining fistula;
• setonswere permitted at screening but were required to be removedby
week 2. Concurrent therapies for Crohn's disease, including stable doses
of5-aminosalicylates, oral corticosteroids, azathioprine, mercaptopurine,
mycophenolate mofetil, methotrexate,and antibiotics, were permitted
Exclusion Criteria
• stricture;
• abscess;
• previously been treated with infliximab
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
54 weeks
January21,2000-0ctober17,2001
Yes
Yes
Yes
Yes
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Adverse Events
Placebo Infliximab
(N=144) (N=138)
Adverse events leading to discontinuation
of study agent 12(8) 5(4)
Serious adverse events
All events 33(23) 19(14)
Reasonably related events 9(6) 3(2)
Infections
Infections requiring antimicrobial treatment 39(27) 47(34)
Serious infections 9(6) 4(3)
New fistula-related abscesses 25(17) 17(12)
Infusion reactions 24(17) 22(16)
During induction 11(8) 9(7)
During maintenance 4(3) 13(9)
During treatment after crossover 14(23) 3(9)
Death
Cancer
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Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A
Randomized, Placebo-Controlled Study. Jarnerot G, Hertervig E, Friis-Liby I, et al
Gastroenterology 2005;128:1805-1811
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Infliximab
5mg/kg
• age 18-75 years a diagnosis;
• certain or probable UC;
• exclusion of an infectious cause;
• a severe or moderately severe attack of UC according to the Seo index;
• fulminantcolitisindex>=8.00nday30ra Seo index on day 5,6, or7
that was compatible;
• with a severe or moderately severe attack of UC that was not responding
to corticosteroid treatment
• pregnancy or planned pregnancy in the next 12 months;
• active breast-feeding;
• known or probable Crohn's colitis, infectious colitis;
• ongoing infection such as an abscess;
• central line infection;
• febrile urinary tract infection;
• active tuberculosis or exposure to tuberculosis;
• multiple sclerosis;
• malignancy;
• heart failure or treated heart failure;
• earlier treatment with infliximab or another antibody;
• another disease according to the investigator's judgment;
• psychiatric disease;
• alcoholism or anything else whereby the patient was judged incapableof
completing the trial
1 dose given
July 2001 and the last in January 2004
Yes
Yes
Yes
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Central line sepsis (n = 1)
Arthralgia, kneejoints(n=2)
Upper respiratory infection (n =2)
Pneumothorax when adopting central venous line(n = 1)
Discreteexanthema(?antibioticrelated)(n= 1)
Pruritus during infusion (n = 1)
Perspiration (n = 1)
Long-lasting bleeding from rectal stump(n = 1)
Ileus48daysafterinfusion(n=1)
Nausea, vomiting, abnormal liver tests, pneumonia(n= 1)
Reflux, oral candidiasis(n = 1)
Exanthema(?antibioticrelated)(n=2)
Epigastralgia,reflux,abnormallivertests50daysafterinfusion, probably azathioprine(n= 1)
Headache, 38SOC 14 days after infusion (n = 1)
Ptosis, right eyelid, 32 days after infusion (n = 1)
Dermal sensations during infusion(n= 1)
Arthralgia 90 days after infusion (n= 1)
Cardiac pacemaker 111 daysafterinfusion(n= 1)
Reoperation due to septic complication-referable to rectalstump(n=3)
High fever, CRP >200 5 days after surgery, rectum flushed, normalization (n = 1)
Urinary tract infection, fever, antibiotics(n = 1)
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Rutgeerts 2005
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title:
Treatment Studied
Dose
Inclusion Criteria
Exclusion Criteria
Duration of Treatment
Duration of Study
Randomized
Placebo Controlled
Blinding
Allocation concealment
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts P, Sandborn WJ, Feagan BG, et al. N Engl J Med
2005;353:2462-76
Infliximab
5mg/kg
• ulcerative colitis;
• MAYO score: 6to 12 points;
• moderate-to-severe active disease on sigmoidoscopy (Mayo endoscopic
subscore of at least 2)
• concurrenttreatmentwithcorticosteroidsaloneorincombination with
azathioprine or mercaptopurine in ACT 1;
• concurrent treatment with corticosteroids alone or in combination with
azathioprine or mercaptopurine and medications containing 5-ASA in
ACT 2;
• concurrent therapy was not required at enrollment for patients in ACT 1
and ACT 2 who had had no response to corticosteroids within the
preceding 18monthsorwhocouldnottoleratecorticosteroids, patients
in either study who had had no response to azathioprine or
mercaptopurine within the preceding 5 years orwhocould nottolerate
these drugs;
• in ACT 2 patients who had had no response to medications containing 5-
aminosalicylateswithin the preceding 18 monthsorwhocould not
tolerate such drugs;
• rectally administered corticosteroids or medicationscontaining5-
aminosalicylates were not permitted within two weeks before screening
• positive tuberculin skin tests;
• diagnosis of indeterminate colitis, Crohn'sdisease, orclinicaI findings
suggestiveofCrohn'sdisease(i.e., fistula or granulomas on biopsy);
• patientspreviouslyexposedtoinfliximaboranyotheranti-TNFagent
ACT1: 54 week
ACT 2: 30 week
March 2002 and March 2005
Yes
Yes
Yes
Yes
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Placebo IFX5mg IFX10mg
(N=121) (N=121) (N=122)
103(85.1)106(876)111(91.0)
PLB IFX5mg IFX10mg
(N=123) (N=121) (N=120)
90(732) 99(81.8) 96(80.0)
1(08)
~ :~~:
;(17)
1(0.8) 1(08)
~i~~~~~~n~~~~~Sleading 10
31(25.6) 26(21.5) 29(23.8) 24(19.5) 13(10.7) 11(92)
47(38.8) 53(438) 60(492) 29(23.6) 33(273) 34(283)
25(20.7) 39(32.2) 43(35.2) 15(12.2) 18(149) 17(14.2)
;:~~l 3(2.5) 8(66) ~ (0.8) 2(1.7) 3(2.5)
~ (0.8)
;:;~:
1(0.8) ~ :~~: 1(0.8) ~ (0.8)~ (0.8)
~ (0 8) ~ (0.8) ~ :~~l
0
~ (08)
0
~ (08)
1(08)
1(0.8)
1(0.8)
1(0.8) ~ (08) 0 1(0.8)
0 ~ (0.8)
1(0.8)
1(0.8) 0
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Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Infliximabplusazathioprineforsteroid-dependentCrohn'sdisease patients: A
randomized placebo-controlled triaL(GETAID) Lemann M, Mary JY, Duclos B, et al
Gastroenterology. 2006;130:1054-61
Treatment Studied Infliximab
Dose Infliximab5mg/kgorplaceboatweeksO,2,and6
Inclusion Criteria
• at least 18 years old;
• luminal steroid-dependent CD;
• diagnosisbasedonestablishedclinical,endoscopic,radiologic,and
histologic criteria;
• Steroid dependency: (1) prednisone had to be given for at least 6 months
atadosage 10 mg/dayormore, with no interruption for more than 2
months within the past 6 months; (2) at least 2 clinical luminal relapses
when tapering of steroids had been attempted, leadingtoan increase in
the dose to more than 10mg/day; and (3)thelastattemptforsteroid
tapering had to be within the past 6 months. At baseline, patients had to
be treated with prednisone 10 mg/day or more
• AZN6-MP status at baseline (1) those in the naive stratum who did not
receive AZN6-MP in the past 2 years or (2) those in the failure stratum
who still had clinically active disease (Crohn's Disease Activity Index
[COAl] >= 150) despite receiving AZN6-MP for more than 6 months at a
stable and appropriate dose (2-3 mg/kg/day for AZA and 1-1.5
mg/kg/dayfor6-MP)
• Adequate birth control
Exclusion Criteria
• contraindication to AZN6-MP or to infliximab;
• treatment with an immunosuppressive drug other than AZN6-MP in the
past 6 months;
• previous use of infliximab or other anti-tumor necrosis factor;
• previous use of thalidomide;
• concomitanttreatmentwithaminosalicylates, budesonide, topicaI
steroids, or artificial nutrition;
• symptomatic stricture;
• intra-abdominal abscess or infection;
• severe sepsis within the past 3 months;
• tuberculosis;
• history of Hepatitis B orC;
• human immunodeficiency virus infection;
• liver failure;
• pregnancy;
• breast-feeding;
• participation in pharmaceutical research within the past 3 months
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Duration of Treatment 52 weeks
Duration of Study June 2000 to May 2002
Randomized Yes
Placebo Controlled Yes
Blinding Yes
Allocation concealment Yes
Adverse Events
Infliximab Placebo
(n=57) (n=56)
At Least One Event 29(51%) 28(50%)
Total # Events 79 66
Mild 39 27
Moderate 36 30
Severe 4 9
Pts with at least 1 serious AE 3
Infections
Upper respiratory tract
Dental
Otitis
Cutaneous
Herpesvirus
Urinary tract
Intestinal
Perianal abscess
Pelvic abscess
Arthralgia,myalgia
Abdominal pain, diarrhea
Nausea or vomiting
Headache
Cutaneous rash, pruritus
Fatigue
Reaction to infusion
Fever
Increase of liver enzymes
Pancreatitis
Miscellaneous
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AG. Onercept
Rutgeerts 2006.
Data Extraction Form: The safety of TNF-alpha inhibitors used for the treatment of IBD
Title Onercept for moderate-to-severe Crahn's disease: a randomized, double-blind, placebo-
controlled trial. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Clin Gastroenterol
Hepatol. 2006;4:888-93
Treatment Studied Onercept
Dose Onercept 10, 25, 25 or 50 mg TIW
Inclusion Criteria
• active CD with a COAl between 250 and 400;
• patients with acute active Crahn's disease (AACD) were required to have
received no glucocorticoid treatment for 4 weeks and no
immunosuppressants for 3 months before the start of the study;
• patients with chronic active Crohn's disease (CACD) were defined as
those with active disease despite treatment with oralglucocorticoids
and/orimmunosuppressantsinthe3 months before the start of the
study,
• awhitecellcountof3.5x109/Lormore;
• aneutrophilcountof1.5x109/Lormore;
• a plateletcountof100x 109/Lormore;
• ahemoglobinlevelof8.5g/dLormore;
• maintenance treatment with oral sulfasalazine or mesalamine derivatives
in the4 weeks before the study was allowed
Exclusion Criteria
• prior treatment with cytokines, anticytokines, intercellular adhesion
molecule1,antisenseoligonucleotideoranti-CD4;
• inadequate liver or renal function;
• symptoms of stenosis regarded as mainly noninflammatory;
• presenceofastoma;
• history of small-bowel resection;
• active infection;
• history of cancer;
• need for emergency surgery;
• elective surgery planned during the study
Duration of Treatment
Duration of Study
Randomized
PlaceboContralied
Blinding
Allocation concealment
8 weeks
November 2001 to February 2003
Yes
Yes
Yes
Yes
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Adverse Events
Plb ON10 ON25 ON35 ON50
(n=37) (n=44) (n=42) (n=42) (n=42)
At least 1 AE 26(70.3%) 31 (70.5%) 28(66.7%) 30(714%) 32(76.2%)
Drug-relatedAE 19(514%) 25(56.8%) 22(524%) 27(64.3%) 25(59.5%)
Adverse event possibly
relatedtoanti-TNF 12(324%) 11 (25.0%) 14(333%) 12(28.6%) 16(38.1%)
Injection site erythema 0 2(45%) 4 (9.5%) 9(214%) 7(167%)
Withdraw 3(8.1%) 3(68%) 2(4.8%) 2(48%)
SeriousAE 1(2.7%) 1 (2.3%) 1 (24%) 3(71%)
Antibodies 2(49%) 1 (2.4%) 4(9.8%) 6(143%)
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Appendix C: PRISMA Checklist
141
PRISMA 2009 Checklist
TITLE
1 I Identify the report as a systematic review, meta-analysis, orboth
ABSTRACT
Structured summary
INTRODUCTION
Objectives
METHODS
Protocol and registration
Eligibility criteria
Study selection
21 Provide a structured summary including, as applicable: background;objectives;datasources;studyeligibilitycriteria, I (ii)
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and
implicationsofkeyfindings;systematicreviewregistrationnumber
3 1 Describe the rationale for the review in the context of what is already known
41 Provide an explicit statement of questions being addressed withreferencetoparticipants,interventions,comparisons,
outcomes, and study design (PICOS)
51lndicateifareviewprotocolexists,ifandwhereitcanbeaccessed(e.g.,Webaddress),and,ifavailable,provide
registration information including registration number
61 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., yearsconsidered,
language,publicationstatus)usedascriteriaforeligibility,givingrationale
71 Describe all information sources (e.g., databases with dates ofcoverage, contact with study authors to identify
additional studies) in the search and date last searched
81 Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.
91 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis)
Data collection process
Risk of bias in individual
studies
Summary measures
SynthesIs of results
10 I Describe method of data extraction from reports (e.g., piloted forms, independently,induplicate)andanyprocesses
for obtaining and confirming data from investigators
11 I List and define all variables for which data were sought (e.g PICOS, funding sources) and any assumptions and
simplifications made
121 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
doneatthestudyoroutcomelevel),andhowthisinformationistobeusedinanydatasynthesis
13 I State the principal summary measures (e.g .. risk ratio, difference in means)
14 1 fee;~r:~~~~:a~~t~:~:_~~:~~~~lng data and combining results of studies, if done, including measures of consistency
12
Appendix A
~ PRISMA 2009 Checklist
Risk of bias across studies I 151 Specify any assessment of risk of bias that may affect the cumulativeevidence(e.g., publication bias, selective
reporting within studies)
Additional analyses 161 Describe methods of additional analyses (e.g., sensitivity or sUbgroup analyses, meta-regression), if done, indicating 112
which were pre-specified
RESULTS
Study selection 17 1 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at I 13
each stage, ideally with a flow diagram
Study characteristics 18 I For each study, present characteristics for which data were extracted (e.g., study size, PiCaS, follow-up period) and I Appendix B
provide the citations
Risk of bias within studies I 19 I Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12)
Results of individual studies I 20 I For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot
Synthesis of results I 21 I Present results of each meta-analysis done, including confidence intervals and measures of consistency
Risk of bias across studies 1 221 Present results of any assessment of risk of bias across studies (see Item 15)
Additional analysis I 231 Give results of additional analyses, if done (e.g., sensitivityorsubgroupanalyses, meta-regression [see Item 16))
DISCUSSION
Summary of evidence
FUNDING
Funding
24 I Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to
keygroups(e.g.,healthcareproviders, users, and policy makers)
25 I Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identifiedresearch,reportingbias)
261 Provide a general interpretation of the results in the context 0 fotherevidence, and implications for future research
27 I ~yeS~~~b~i~or~~~::of funding for the systematic review and other support (e.g .. supply of data); role of funders for the I ~~~Iicable
From Moher D. Liberati A, Tetzlaff J. Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses The PRISMA Statement. PLoS Med 6(6). e1000097
da110.13711jaurnalpmed1000097




